Vision Gain Pharma Reports

Visiongain ltd.
4th Floor,
BSG House,
226 236 City Road,
London
EC1V 2QY
United Kingdom
Telephone: +44 (0) 20 7336 6100

Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
http://www.visiongain.com
Stem Cells – The Hype & Hope – World Analysis 2009-2024
Report Details
Stem cells represent one of the most promising medical breakthroughs of all time, as our
new market report explains. Currently, in 2009, the new US administration is lifting some
major restrictions on stem cells technologies. This developmental obstacle now removed,
all types of stem cells are available for expanding the therapeutic and commercial
potentials.
Stem cell technologies – changes to US regulations to give exciting new hopes and
potentially vast commercial opportunities – brand new indepth study
Stem cells represent one of the most promising medical breakthroughs of all time, as our
new market report explains. Currently, in 2009, the new US administration is lifting some
major restrictions on stem cells technologies. This developmental obstacle now removed,
all types of stem cells are available for expanding the therapeutic and commercial
potentials, as our new report Stem Cells – The Hype & Hope – World Analysis 2009-2024
explains. Based upon the cells that create and renew all tissues potentially, stem cell
therapies could revolutionise the treatment of disease, especially through tissue and organ
replacement. Stem cells could provide revolutionary treatments for conditions from
diabetes to multiple sclerosis, and from myocardial infarction to chronic obstructive
pulmonary disease, amongst many others. Stem cell lines could also change the way
pharmaceutical companies assess new chemical entities during R&D.
A conservative estimate places the potential market value of stem cells at over $150bn by
late next decade. But will stem cell products be ready to meet regulatory hurdles and
market requirements? Where is stem cell research heading today? What stem cell therapies
are likely to hit the market from 2009 onwards? Where does the highest value lie in the
short-term? What are the commercial threats there? This new visiongain report answers
these and other crucial questions about this important developing field, one with vast
commercial potential.
Comprehensive analysis of the global stem cells sector and market

Stem Cells – The Hype & Hope – World Analysis 2009-2024 examines stem cells
technology critically. We used a comprehensive review of information sources, including
consultations with relevant experts. This report provides detailed sales forecasts,
discussions of pipeline developments and analyses of important contemporary issues,
especially relevant commercial drivers and restraints. This report also covers regulations
and ethics. Sources used include commercial databases, industry news, published reports,
policy documents and economic research. Importantly, visiongain applied rigorous
financial forecasting, qualitative analyses and the assessment of unmet needs. The result is
a comprehensive market- and industry-centred report with detailed analysis and informed
opinion that you will not find elsewhere.
Why you should buy this report:

Key information that you will find in Stem Cells – The Hype & Hope – World Analysis
2009-2024 includes:
• Analyses of the existing market value for stem cells
• Analyses of the potential market value of stem cell therapies, including detailed revenue
forecasts from 2009 to 2024
• Forecasts for existing stem cell markets, including private cord blood banks and Osiris
Therapeutics and NuVasive’s Osteocel
• Discussions of ethical complications and situations that influence the way stem cell
medicine is perceived, researched and conducted
• Analyses of key organisations, suppliers and relevant national laws
• Expert opinions from original research interviews with key opinion leaders in stem cells
research and technology
• Informed analyses of the strengths and weaknesses of the technologies from 2009
onwards
• Balanced assessments of commercial drivers and restraints in the stem cells field.
• Visiongain believes that stem cell technologies are progressing rapidly. We predict that
more products will enter the market over the coming 5 years, changing the commercial
landscape for stem cells.
You can order this report today

Nobody with an interest in the stem cells field can afford to overlook this new market
study from visiongain. The market environment in many countries will change, especially
after favourable developments in the US in early 2009. Visiongain predicts that revenues
for stem cell technologies will increase greatly from 2009 to 2024, with important events
shaping trends. Will stem cells revolutionise medicine in the foreseeable future? What are
the main obstacles to overcome there? What revenues can be achieved? This report covers
those vital questions and many more. Do you want to know more about this important
market? You can stay ahead in this exciting field by ordering this report today.
http://www.visiongain.com/Report.aspx?rid=376
The Global Multiple Sclerosis Market 2009-2024
The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those
revenues will exceed $9bn during the second half of next decade, our new study shows.
This report will provide you with the analytical information that you need to understand
current trends and future directions in the MS market area, the successful drugs being
introduced and where the future successful growth of the market lies.
Report Details
Global Multiple Sclerosis Market will expand steadily from 2009 to 2024 - new report
explains
The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those
revenues will exceed $9bn during the second half of next decade, our new study shows.
The World Health Organization estimates that over 2.5 million people suffer from multiple
sclerosis worldwide. The prevalence and onset of MS in children and adults is expected to
rise steadily. Global sales for MS therapies will rise accordingly, due to epidemiological,
healthcare and commercial drivers. In this new market-based study - The Global Multiple
Sclerosis Market 2009-2024 – we show and explain those trends in detail. This report will
provide you with the analytical information that you need to understand current trends and
future directions in the MS market area, the successful drugs being introduced and where
the future successful growth of the market lies.
The Global Multiple Sclerosis Market 2009-2024 commercially analyses both leading and
emergent treatments, with key companies and products discussed comprehensively. In
particular, we discuss prospects for the following MS drugs:
- Tysabri
- Avonex
- Copaxone
- Betaferon
- Rebif.
Contemporary disease-modifying drugs for MS are administered intravenously,

intramuscularly or subcutaneously, typically with discomfort to patients. We believe that
orally-administered MS products will change the dynamics of the market area significantly.
But you must understand now the commercial opportunities for those new agents and other
exciting pipeline developments. This report answers those important questions and others,
such as how the established MS products will fare competitively in the years ahead. Which
will remain the most profitable and how will they be effected by new competition.
Comprehensive Market Analysis
The Global Multiple Sclerosis Market 2009-2024 examines the market sector critically
through a comprehensive review of information sources, including first-hand primary
consultations with relevant experts. This report provides detailed sales forecasts,
discussions of pipeline developments and analyses of important contemporary issues,
especially relevant commercial drivers and restraints. Sources used include gold-standard
commercial databases, in-house analytical tool, industry news, published reports, policy
documents and economic research. Importantly, visiongain applies rigorous financial
forecasting, qualitative analyses and the assessment of unmet needs. The result is a
comprehensive market- and industry-centred report with detailed analysis and informed
opinion.
Why you should buy The Global Multiple Sclerosis Market 2009-2024
By purchasing this report, you will receive the following benefits:
• Predicted revenues, growth rates and other key metrics for the global MS drugs market
from 2009 to 2024
• Predicted revenues, growth rates and other key metrics for leading MS drugs worldwide
from 2009 to 2024
• Predicted revenues, growth rates and other key metrics for MS drug sales in leading
nations from 2009 to 2024
• Expert opinions from original visiongain interviews, with full interview transcripts – you
will not find this information anywhere else
• Discussion of hot pipeline developments and up-and-coming products
• Discussion of forces that influence and characterise the market for MS treatments
worldwide:
- Competitive characteristics of the market
- Drivers
- Restraints
- Strengths, weaknesses, opportunities and threats
• Discussion of where the market is heading overall - both technologically and
commercially - from the present onwards.
Nobody with an interest in the MS sector can afford to overlook this new market study
from visiongain. Visiongain predicts that total revenues in the MS market will increase
steadily throughout the forecast period, 2009 to 2024, with the most substantial growth
occurring during a crucial period in the future. The market environment in many countries
will change, with patent losses affecting current market leaders in MS treatment. New drug
releases and reformulations of products will seek to increase therapeutic effectiveness,
especially patient compliance. A new wave of oral drugs, currently in development, may
well change the way MS treatments are delivered. Do you want to know more about this
important market? You must order this report today.
Statins: The World Market, 2009-2024
The world statins market is changing, with patent expires and maturity of the landmark
product Lipitor (atorvastatin). Statins are at the forefront of strategies to combat
dyslipidaemia, being pivotal in the prevention of coronary heart disease. Consequently,
those drugs are one of the most widely-prescribed and most lucrative sectors of the
pharmaceutical industry, with total revenues exceeding $26 billion in 2008.
Report Details
The world statins market is changing, with patent expires and maturity of the landmark
product Lipitor (atorvastatin). Statins are at the forefront of strategies to combat
dyslipidaemia, being pivotal in the prevention of coronary heart disease. Consequently,
those drugs are one of the most widely-prescribed and most lucrative sectors of the
pharmaceutical industry, with total revenues exceeding $26 billion in 2008. Importantly,
the world statins market is poised to undergo a period of rapid and dynamic change, with
the generic statin sector growing particularly strongly in the years ahead. When will annual
sales of generic statins exceed those of branded statins? Which branded statin will continue
to achieve year-on-year sales growth during the coming waves of generic competition?
Statins: The World Market, 2009-2024 answers these vital questions – amongst others - and
provides the essential information that you need to take advantage of opportunities in the
changing statin drugs market from 2009 onwards.
Statins: The World Market, 2009-2024 provides a comprehensive analysis of the world
statins market, compiled using a wealth of research tools – including interviews with key
opinion-leaders, examination of commercial databases, company reports, policy
documents, industry news and filings. This original study provides extensive sales
forecasting, market shares present and future, informed opinion, as well as detailed
analysis of unmet needs, pipeline developments and commercial opportunities for statin
drugs.
Highlights of Statins: The World Market, 2009-2024 include:

• Forecasts to 2024 for the overall world statin market, the generic statin market, the
branded statin market and the dyslipidaemia market, including all statin types, the leading
statin brands, leading manufacturers, country markets and combination statin drugs
• Interviews with key-opinion leaders in the field
• Examination of strengths, weakness, opportunities and threats facing major stakeholders
in the sector – the market drivers and restraints
• Analysis and forecasts for the leading statin markets in the US, Japan and Canada,
together with leading European and emerging national markets
• Analysis of the R&D pipeline for new statins, as well as other lipid-lowering drug types.
With full market forecasts for all the major generic statins, this new visiongain report
reveals the significant commercial opportunities in new sectors of the statin market.
However, significant opportunities exist for original branded products too. With relatively
few single statins currently in development, new product developments in statins will
mainly focus on statin combination drugs, visiongain predicts. In addition, strong growth
in the statins sector will occur in emerging national markets - most notably in China and
India - driving global sales. There are vast and expanding existing and potential patient
populations for those drugs worldwide.
Importantly, there are opportunities for companies to raise sales by maximising patient
compliance and accessing new patient groups. Statins: The World Market, 2009-2024
examines strategies for increasing patient compliance there. The report has detailed
interviews with key-opinion leaders in this important field. Full interview transcripts are
provided – you will not find this information anywhere else.

• To receive a comprehensive analysis of the prospects for statins from 2009-2024,
including predicted revenues, growth rates, market shares and other key metrics
• To identify key pipeline developments and up-and-coming products, both in the field of
statins, and for other lipid-lowering therapies
• To discover the drivers, restraints, competition and opportunities influencing the global
statins market –for leading brands, generics and statin combination drugs
• To receive forecasts for leading statin country markets and major emerging markets for
statin drugs, including China and India
• To find out where that market sector is heading - both technologically and commercially -
from the present onwards.
Statins: The World Market, 2009-2024 is essential reading for everybody involved in the
statins market, revealing prospects for both existing competitors and potential market
entrants from the present onwards.
Inflammatory Bowel Diseases: World Market Report 2009-2024

This brand new in-depth market analysis examines the current and future prospects of the
inflammatory bowel diseases (IBD) market. The world market for intestinal anti-
inflammatories was worth over $2400 million in 2008, and had grown at 9% over the
previous year.
Report Details
previous year.
The value of other types of drugs used to treat IBD, including immunosuppressants and
monoclonal antibodies, approached $12000m. Visiongain predicts the market for intestinal
anti-inflammatories and IBD drugs to continue expanding, based on rising disease rates
and evolving diagnostic methods. Currently, IBD is under-diagnosed, especially in
developing countries. As governments and health services address chronic illnesses like
IBD, this market will expand into previously untreated regions. Continuing studies and
surveys indicate that IBD is spreading globally, and has an especially high prevalence rate
in India. In addition, the Latin American countries experienced 14% sales growth last year,
and are set to account for an increasingly large share of the world market in years to come.
This report – Inflammatory Bowel Diseases: World Market 2009-2024 - discusses and
analyses the major drug categories used in the treatment of IBD. This report forecasts the
top brand-name and generic drugs used for IBD, including monoclonal antibody therapies.
How much of an impact will monoclonal antibodies have on sales of other IBD-related
therapies, for example? You should know and ths report will tell you. This report also
analyses the major markets worldwide, discussing the principal national markets in detail,
in addition to the world market. Through this report, you will discover how the leading
markets will perform in the future, and how the relative values of each region will change
over time. The US was the largest market in 2008, but will it retain its leading market share
until 2024? How will the European market share compare with the Asian market share in
2014, 2019 and 2024?
Drug types analysed and forecasted in this report – Inflammatory Bowel Diseases: World
Market 2009-2024 - include:
• Aminosalicylate acid / 5-ASA
• Corticosteroids
• Immunomodulators
• Antibiotics
• Biologic therapies
• Monoclonal antibodies.
• Includes unique primary material unavailable elsewhere
This report covers disease and therapy distinctions between the two major types of IBD:
Crohn’s disease and ulcerative colitis. It discusses these diseases and addresses aetiological
theories that impact upon treatment. We provide the information you need to assess the
future of those diseases and of the relevant markets. Sources consulted include industrial
databases, commercial information, published economic research and market-specific
interviews with experts in the IBD field. The result is a comprehensive market- and
industry-based report with detailed analyses and informed opinion that you will not find
anywhere else.
In particular, Inflammatory Bowel Diseases: The World Market 2009-2024 focuses on the
following essential aspects of that market:
• Forecast of the overall world IBD market from 2009 to 2024
• Forecasts of the current leading drugs’ sales from 2009 to 2024
• Assessments of pipeline developments
• Analyses of short- and long-term drivers in the market
• Analyses of how disease theories impact upon treatment procedures
• Sales forecasts for the leading regional markets from 2009 to 2024, including discussions
of specific country markets
• Discussion of the importance of generics in the IBD market
• Discussion of why the market contains so many types of drugs, and what that means for
future developments
• Assessments of opportunities and threats in the IBD market worldwide
• Analyses of the impact monoclonal antibodies will have on the IBD market, present and
future.

• To receive a comprehensive assessment of the complex IBD market, including the
various types of therapies
• To receive a comprehensive analysis of the sales prospects for existing and new IBD
drugs from 2009 to 2024
• To discover which types of therapies are most likely to succeed over the short- and long-
term, and why each will succeed
• For a thorough assessment of the current and future market at global and regional levels
• To find out where the market is heading, both technologically and commercially
• For a logical analysis of the multifaceted treatment options for IBD, including market
drivers and restraints.
The global IBD market is highly complex, with multiple drugs being used simultaneously
and/or sequentially for therapy. The market can therefore accept a large number of drugs,
but the market is already fairly saturated, with several similar drugs on the market. What
does such saturation mean for the futures of existing drugs? What does this mean for the
pipeline? If, as visiongain’s interviewees say, IBD current drugs are less efficacious than
they could be, what then are the promising future treatments that could fill therapeutic
gaps? This report covers those important matters, amongst others.
As inflammatory bowel disease rates continue to rise, as too public awareness spreads and
more-thorough diagnostic procedures expand the number of patients, the demand for IBD
drugs will increase. What drugs and which companies will meet these therapeutic needs
successfully in the future? Can new and future therapies compete successfully with
established treatments? This report answers those and other important questions, to enable
you to take advantage of this expanding market.
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024

Obesity has been described as a 'public health time-bomb'. In 2005, the World Health
Organization estimated that approximately 400 million individuals are obese. Prevalence of
obesity is rising worryingly in many countries, despite campaigns emphasising the link
between being overweight and contracting diabetes. This new report - Anti-Obesity
Treatments 2009-2024 – explains those trends in commercial terms.
Report Details
previous year.
The value of other types of drugs used to treat IBD, including immunosuppressants and
monoclonal antibodies, approached $12000m. Visiongain predicts the market for intestinal
anti-inflammatories and IBD drugs to continue expanding, based on rising disease rates
and evolving diagnostic methods. Currently, IBD is under-diagnosed, especially in
developing countries. As governments and health services address chronic illnesses like
IBD, this market will expand into previously untreated regions. Continuing studies and
surveys indicate that IBD is spreading globally, and has an especially high prevalence rate
in India. In addition, the Latin American countries experienced 14% sales growth last year,
and are set to account for an increasingly large share of the world market in years to come.
This report – Inflammatory Bowel Diseases: World Market 2009-2024 - discusses and
analyses the major drug categories used in the treatment of IBD. This report forecasts the
top brand-name and generic drugs used for IBD, including monoclonal antibody therapies.
How much of an impact will monoclonal antibodies have on sales of other IBD-related
therapies, for example? You should know and ths report will tell you. This report also
analyses the major markets worldwide, discussing the principal national markets in detail,
in addition to the world market. Through this report, you will discover how the leading
markets will perform in the future, and how the relative values of each region will change
over time. The US was the largest market in 2008, but will it retain its leading market share
until 2024? How will the European market share compare with the Asian market share in
2014, 2019 and 2024?
Drug types analysed and forecasted in this report – Inflammatory Bowel Diseases: World
Market 2009-2024 - include:
• Aminosalicylate acid / 5-ASA
• Corticosteroids
• Immunomodulators
• Antibiotics
• Biologic therapies
• Monoclonal antibodies.
• Includes unique primary material unavailable elsewhere
This report covers disease and therapy distinctions between the two major types of IBD:
Crohn’s disease and ulcerative colitis. It discusses these diseases and addresses aetiological
theories that impact upon treatment. We provide the information you need to assess the
future of those diseases and of the relevant markets. Sources consulted include industrial
databases, commercial information, published economic research and market-specific
interviews with experts in the IBD field. The result is a comprehensive market- and
industry-based report with detailed analyses and informed opinion that you will not find
anywhere else.
In particular, Inflammatory Bowel Diseases: The World Market 2009-2024 focuses on the
World Diabetes Market Analysis, 2009-2023
Incidence and prevalence of diabetes mellitus are increasing worldwide, in line with
lifestyle changes and population aging. In particular, the rising prevalence of diabetes is
closely linked with that of obesity, creating significant market opportunities. The World
Health Organization estimates the number of diabetics to exceed 350 million by 2030.
Governments and other healthcare providers around the world are investing in health
education, diagnosis and treatments for this chronic, debilitating - but controllable -
disorder.
Report Details
Incidence and prevalence of diabetes mellitus are increasing worldwide, in line with
lifestyle changes and population aging. In particular, the rising prevalence of diabetes is
closely linked with that of obesity, creating significant market opportunities. As discussed
in this new visiongain report - World Diabetes Market Analysis, 2009-2023 - The World
Health Organization estimates the number of diabetics to exceed 350 million by 2030.
Governments and other healthcare providers around the world are investing in health
education, diagnosis and treatments for this chronic, debilitating - but controllable -
disorder.
In 2007, the diabetes treatment market worldwide was worth over $25 billion, and had
double-digit growth from the year before. Consequently, it is one of the largest sectors in
the global healthcare industry. All segments of the diabetes therapy market have been
expanding, but which will grow fastest in years to come? What are the key therapeutic and
commercial trends to watch? How will the principal national markets perform from 2009
to 2023? What will happen to the current leading products/therapies? How does diabetes
overlap with obesity? This report will answer those and other crucial questions about this
large, increasingly important pharmaceutical market.
This visiongain report - World Diabetes Market Analysis, 2009-2023 - provides in-depth
analysis of the markets for insulins, insulin analogues and oral anti-diabetics. This report
also covers the new GLP-1 analogues – such as Byetta and liraglutide - as well as
potentially revolutionary insulin delivery technologies. Our study includes detailed sales
forecasts for crucial products and market areas, providing the information you need to
assess commercial aspects of the diabetes market fully. We cover both sales worldwide and
for leading national markets, present and future. In addition to consultation with relevant
experts - including interview transcripts - this original research involved a detailed study of
policy documents, industrial reports and current developments, including R&D pipelines
and line extensions. Importantly, visiongain applied techniques such as financial
forecasting and analyses of market drivers and restraints. The result is a comprehensive
market- and industry-based report with detailed analyses and informed opinion that you
will not find anywhere else.
Highlights of World Diabetes Market Analysis, 2009-2023 include:
• Analyses of the strengths, weaknesses, opportunities and threats that will affect the global
diabetes market, particularly drivers and restraints
• Sales forecasts for major drugs and discussion of prominent companies’ activities
• Separate analyses and forecasts for the oral anti-diabetics and insulin analogues markets
• Regional analyses for the United States, Europe, Japan, China and India, all divided into
sales forecasts for oral anti-diabetics and insulin analogues
• Expert opinion - derived from original research interviews - discussing diabetes research,
promising drugs and the commercial and therapeutic significance of the obesity epidemic
on diabetes incidence and treatment, present and future
• Analyses of crucial future trends, including ultra-long-acting drugs and novel insulin-
delivery technologies, as well as more-radical developments.

• To receive forecasts of global revenue trends for diabetes treatments from 2009 to 2023
• To gain in-depth sales forecasts, from 2009 to 2023, covering strengths and weaknesses
of key products and sub-markets
• To gain an understanding of all sectors of the diabetes market, including commercial
analyses of individual drugs, drug classes, pipelines and regional markets
• To discover insight from original interviews with key opinion leaders (KOLs)
• To find out how the diabetes market is set to change dramatically over the next fifteen
years
• To discover how the diabetes management sector is evolving worldwide in terms of
diagnosis, assessment, treatment and patient compliance
• To discover exactly why diabetes is a major concern for governments, and why this
serious chronic illness is one of the most important global healthcare issues, with hundreds
of millions of people suffering from diabetes and hundreds of million more currently at
risk
Visiongain predicts continuing expansion of the market for the whole range of diabetes
treatments, driven by increasing disease incidence as well as improvements to diagnoses
and treatment access, especially in developing countries. Successful participating
companies will benefit as a result, gaining market prominence from high-value products.
The healthcare industry cannot afford to ignore current developments in diabetes treatment,
as shown in this report. Diabetes is arguably the greatest healthcare threat in developed
countries and a rising scourge in countries such as China, India and Brazil. Pharmaceutical,
biotechnological and diagnostics companies cannot afford to overlook this developing
field, especially for innovative therapies.
...more details
Smoking Cessation Report, 2009-2024
Smoking is the leading cause of preventable death in the world. The effects of smoking
represent a global pandemic of enormous proportions. Currently-marketed smoking
cessation aids typically lack high levels of efficacy in practice and are associated with
marked side-effects. There are clear market opportunities for novel, more-efficacious and
safer smoking cessation agents, in both prescription and OTC forms.
Report Details
Smoking is the leading cause of preventable death in the world. The effects of smoking
represent a global pandemic of enormous proportions. Currently-marketed smoking
cessation aids typically lack high levels of efficacy in practice and are associated with
marked side-effects. There are clear market opportunities for novel, more-efficacious and
safer smoking cessation agents, in both prescription and OTC forms.
In 2008, total sales of prescription and OTC smoking cessation products amounted to over
$3bn worldwide. Smoking Cessation, 2009-2024 forecasts how this market will grow and
develop from 2009 to 2024. Visiongain predicts that launches of nicotine vaccines from
2011 onwards will alleviate some of the currently-unmet needs in smoking cessation.
Which nicotine vaccine will be first to market? Smoking Cessation, 2009-2024 answers
that question and many others, providing expert-opinion and analyses on the development
of smoking cessation products of many types, dealing with both pipeline and marketing
developments in the sector.
During the next 15 years, overall growth in the world smoking cessation market will be
increasingly contributed by the BRIC (Brazil, Russia, India and China) group of countries.
Nearly half of the world’s smokers live in BRIC areas, yet those country markets yielded
low per capita smoking cessation revenues in 2008. Smoking Cessation, 2009-2024
analyses the BRIC smoking cessation markets and their prospects for future growth,
revealing how their market shares will increase from 2009 to 2024. This report also
analyses the current-leading markets in North America, Europe and Asia in detail.
Smoking Cessation, 2009-2024 is a comprehensive analysis of the world smoking cessation

market, compiled using a wealth of research tools – including interviews with key opinion-
leaders, examination of company reports, press-releases and filings, use of commercial
databases and analyses of unmet needs and market opportunities. Highlights include:
• Forecasts for the world smoking cessation market, leading therapy types, brands and
individual country markets.
• Detailed examination and market forecasts for the individual country smoking cessation
markets in the US, Canada, Brazil, the UK, France, Germany, Sweden, Russia, Japan,
China and India.
• Examination of strengths, weakness, opportunities and threats (SWOT) facing major
stakeholders in the industry.
• In-depth analysis of the pharmacological pipeline for new smoking cessation products.

• To receive a comprehensive analysis of the prospects for smoking cessation therapies
from 2009-2024, including predicted revenues, growth rates and other key metrics.
• To discover the fate of Pfizer’s Chantix/Champix, in light of recent safety-concerns.
• To identify key pipeline developments and up-and-coming products.
• To discover the forces, restraints, competition and opportunities influencing each of the
separate areas of the smoking cessation market, including nicotine replacement therapies,
Pfizer’s Chantix/Champix and bupropion drugs.
• To find out where the market is heading - both technologically and commercially - from
the present onwards.
The majority of smokers worldwide do not have full access to smoking cessation therapies.
Smoking prevalence is increasing overall, with increases mainly contributed by developing
countries. Adverse health effects and the high economic costs associated with tobacco
smoking are encouraging increasingly-stringent smoking legislation and encouraging
governmental spending on anti-smoking aids. From 2009 to 2024, the continuing
introduction and implementation of tobacco-control policies will accelerate, further
encouraging people to stop smoking, in turn increasing the use of smoking cessation
products. This report demonstrates how the smoking cessation market will expand
worldwide as a result.
Smoking Cessation, 2009-2024 shows that new smoking cessation drugs will enjoy
commercial success only if these are clearly tolerable and more-effective in practice, easily
accessible, backed by innovative marketing campaigns and delivered in combination with
behavioural support programmes. Smoking cessation drugs with these characteristics will
overcome regulatory hurdles and achieve adequate reimbursement from cost-conscious
healthcare providers.
This report is essential reading for everybody involved in the smoking cessation market,
revealing prospects for both existing competitors and potential market entrants, from the
present onwards.
...more details
Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics - 2009-2023

The global market for ophthalmic pharmaceuticals is a large and profitable segment of the
healthcare market, with ophthalmic sales of over $10bn in 2007. The recent therapeutic and
commercial success of Lucentis has increased the number of blockbuster ophthalmic drugs
and highlighted the lucrative commercial rewards on offer in this sector. Which will be the
blockbusters of the future?
Report Details
The global market for ophthalmic pharmaceuticals is a large and profitable segment of the
healthcare market, with ophthalmic sales of over $10bn in 2007. The recent therapeutic and
commercial success of Lucentis has increased the number of blockbuster ophthalmic drugs
and highlighted the lucrative commercial rewards on offer in this sector. Which will be the
blockbusters of the future? This cutting-edge visiongain report provides the answer – and
other essential information that you need to understand the ophthalmic pharmaceutical
sector.
"In 15 years, I expect there will be one or more neuroprotective drugs on the market," says
a leading expert, interviewed for this visiongain report - Ophthalmic Pharmaceuticals,
2009-2023. The report identifies these future blockbuster drugs and goes on to reveal two
currently-untreatable or recalcitrant therapeutic areas with significant unmet need and
greatest potential for market growth.
Ophthalmic Pharmaceuticals, 2009-2023 - provides an in-depth analysis of the ophthalmic

market, using a wealth of research tools - including sales forecasting, qualitative analyses,
probing interviews with industry experts, literature searches and use of commercial
databases. The report is packed with original data in tables, charts and other formats.
Visiongain predicts that the global ophthalmic pharmaceutical market will grow steadily
from 2009-2023, driven by increasing prevalence of ophthalmic disorders amongst an
expanding population of older people. In some countries the market will expand rapidly in
coming years, whilst in others the market will stagnate. By purchasing this report, you will
find out by how much the ophthalmic market will grow and which countries will achieve
most rapid sales growth.
Highlights of Ophthalmic Pharmaceuticals, 2009-2023 include:

• Forecasts for the global ophthalmic market, key therapeutic categories and leading brands
from 2009 to 2023
• Expert opinion from key-opinion leaders in the ophthalmic pharmaceutical sector
stakeholders in that industrial sector
• In-depth analysis of the ophthalmic pharmaceutical pipeline
• Analysis and forecasts for the principal national markets, including the US, Japan, Brazil,
India, China and leading European markets.

• To receive a comprehensive analysis of the prospects for ophthalmic drugs, including key
metrics and predicted revenues, by therapeutic category and brand
• To discover the forces, restraints, competition and opportunities influencing each of the
separate ophthalmic markets, including anti-glaucoma, retinal disorder, dry eye and
ophthalmic allergy, inflammation and infection
• To read the views of experts in the industry, regarding current and future trends,
opportunities and drivers. The report includes full transcripts of interviews – information
that you will not find anywhere else
• To find out how the ophthalmic pharmaceutical market is progressing worldwide - both
technologically and commercially
This visiongain report provides a comprehensive pipeline analysis showing how a range of
drugs - from simple anti-infective agents to advanced molecular treatments – combined
with a wider range of drug delivery systems should aid the restoration of vision or the
cessation of vision loss.
Success in the ophthalmic pharmaceutical market from 2008 to 2023 will be characterised
by the launch of products with superior efficacy, safety and tolerability. Ophthalmic
Pharmaceuticals, 2009-2023 shows how emerging technologies that increase clinical
effectiveness and/or increase patient compliance will be particularly important
therapeutically and commercially.
...more details
The World Dermatological Market Outlook, 2009-2023

This new market analysis by visiongain is to examine the current and future prospects for
the world dermatological market. The world dermatological market generated total sales
revenues of over $18bn in 2007. Visiongain predicts that this market area will expand
further, increasing its total revenues significantly based on expansion of the market for
modern drugs to treat skin disorders in developing countries, most notably China, India
and Brazil
Report Details
This new market analysis by visiongain is to examine the current and future prospects for
the world dermatological market. The world dermatological market generated total sales
revenues of over $18bn in 2007. Visiongain predicts that this market area will expand
further, increasing its total revenues significantly based on expansion of the market for
modern drugs to treat skin disorders in developing countries, most notably China, India
and Brazil. This report will outline the developments and explain their significance.
All the main dermatological market segments achieved positive sales growth from mid
2007 to mid 2008, giving hope for further gains. Dermatitis, anti-infectives and anti-acne
treatments ranked as the top three therapeutic areas according to their sales performance. In
this unique clear report, you will find out how those therapeutic areas and others fare from
2009 to 2023, as well as the performance of leading products there. This one-stop shop of
information will deliver to you the performance of the current leading national markets for
the products during that forecast period – will the US still dominate by such a large margin
in 2013, 2018 and 2023?
This visiongain report - The World Dermatological Market Outlook, 2009-2023 - will
specifically analyse the world markets for the following classes of dermatological
treatments, with relevant sales forecasts:
• Dermatitis treatments
• Anti-infective agents
• Acne treatments
• Psoriasis treatments
• Miscellaneous dermatological agents.
The World Dermatological Market Outlook, 2009-2023 examines the market critically
through a comprehensive review of available information. This detailed report also
highlights pipeline developments and important contemporary issues, especially
commercial drivers and restraints. Sources used include industrial databases, commercial
news, published reports and economic research. Importantly, visiongain applied financial
forecasting, qualitative analyses and the assessment of unmet needs to provide a
comprehensive market-centred report with detailed analysis and informed opinion.
In particular, The World Dermatological Market Outlook, 2009-2023 concentrates on the

• Forecast of the worldwide dermatological market from 2008-2023
• Forecasts of the leading market segments from 2008-2023
• Drivers and restraints facing the world dermatological market
• Opportunities and threats facing the world dermatological market
• Commercial prospects for the market-leading drugs, with global sales forecasts from
2008-2023
• Sales forecasts for the leading country markets from 2008-2023
• Analysis of pipeline developments in the sector
• Discussion of unmet therapeutic needs and relative advantages of products.

• To receive a comprehensive analysis of the prospects for dermatological drugs from
2008-2023
• To discover predicted revenues, growth rates and other key metrics for leading
dermatological treatments from 2008-2023
• To discover "hot" pipeline developments and up-and-coming products
• To determine the forces that influence and characterise the market for dermatological
treatments:
- Competitive characteristics of the market
- Drivers
- Restraints
- Strengths, weaknesses, opportunities and threats
• To find out where the market is heading - both technologically and commercially - from
the present onwards.
The global dermatological treatments market has marked strengths and advantages, but is
also limited by problems and concerns, like some other major pharma sectors. Growth of
generics and biotechnological products create new opportunities. Clearly, that market
sector will be driven by product launches and reformulations of existing drugs.
Furthermore, the incidence of skin diseases is increasing, combined with an increased
demand for treatments, especially in fast-developing nations. Visiongain believes that the
global dermatological market has strong growth potential for both original branded and
generic products. Market expansion will be heavily dependent on reformulations of
existing products for improved drug delivery, new dosing schedules and targeting of
specific patient populations. There are also promising dermatological agents currently in
development; as discussed in this report, some of those potential market entrants have
significant commercial potential. This report is essential reading for everybody involved in
the dermatological treatments market, revealing prospects for both existing competitors
and potential market entrants, from the present onwards.
...more details
Top-10 Biotech Companies - Market Outlook, 2008-2023

The biotechnology industry is a major growth area in the global healthcare market, one
upon which many companies are placing their hopes. Due to developments in monoclonal
antibodies, genomics and proteomics - amongst others - the biotechnology market has
experienced great expansion since its emergence during the 1970's.
Report Details
experienced great expansion since its emergence during the 1970's. The leading healthcare
biotechnology company, Amgen, is now amongst the largest pharmaceutical companies in
the world, with other healthcare biotech companies catching up. The global biotech drug
market was worth over $75bn in 2007, with double-figure growth noticeably higher that
that of the overall pharmaceutical market. Our new report - Top-10 Biotech Companies -
Market Outlook, 2008-2023 - will help you to understand those developments and their
significance. That report provides valuable commercial information on this exciting
industry that no healthcare company should ignore.
Over the period 2008 to 2023, visiongain foresees the healthcare biotechnological market
continuing its strong growth, with exciting new developments both technologically and
commercially. Increased R&D efforts, shorter approval times and innovative new
treatments are aiding market growth. However, the two major threats the healthcare
biotechnology sector faces in the coming years are the increasing threat of biogenerics and
the difficulty in acquiring capital. Strategic partnerships will continue to be important to
biotechnological drug development. There remain significant unmet needs in this market,
with great opportunities for companies that can develop safer and better-targeted
treatments.
Top-10 Biotech Companies - Market Outlook, 2008-2023 examines the product portfolios
of the leading companies critically, with in-depth analysis, especially market forecasting
and qualitative analysis of market drivers and restraints. The result is a comprehensive
market-based report with detailed analysis and informed opinion.

In particular, Top-10 Biotech Companies - Market Outlook, 2008-2023 concentrates on the
following essential aspects of the healthcare biotech market:
• Achievements and aspirations of global healthcare biotechnology
• Detailed sales forecasts from 2008-2023 for the sector, leading biotech companies and
their main products
• Issues affecting the sector
• Discussion of drivers and opportunities
• Discussion of restraints and threats
• Detailed analyses of the top-10 healthcare biotech companies from 2008 onwards
• Salient pipeline developments in biotechnology and their implications for the future.
In 2007, the global revenues generated by the top-10 biotech companies exceeded $45bn.
Amgen, Genentech and UCB are good examples of leading companies that have
experienced strong sales growth in recent years. Principal drugs developed and marketed
by the leading companies include Aranesp, Mabthera and Keppra, each with blockbuster
sales. Moreover, pipelines of the leading biotech companies remain strong.
The leading healthcare biotechnology companies will continue to make strong inroads into
the overall global pharma industry and market in the years ahead, with rising stars
competing too. Do you know how sales of leading biotech companies will develop over the
coming years? Do you know the prospects for other biotech organisations? Visiongain
concludes that there will be increasing reliance on biological drugs as time goes by,
especially for recalcitrant diseases with significant unmet needs. The commercial and
technological opportunities for greater personalisation of medicine through biotechnology
are very exciting. Certainly, the commercial opportunities for dynamic healthcare biotech
companies are significant. The development of more-personalised medicine promising
greater efficacy and safety - particularly in cancer treatment - is a major commercial hope.
By purchasing this report, you will be better prepared to appreciate those major
developments in the global pharmaceutical market.
...more details
World Generics Market, 2008-2013
The generics market remains a major growth area in the global healthcare market. That
growth has been partly driven by cost-containment in several national healthcare sectors,
with governments seeking to promote the use of generic products over higher-priced
originator products. The global generic pharmaceuticals market was worth over $100bn in
2007, with market growth noticeably higher that that of the overall pharmaceutical market.
Report Details
The generics market remains a major growth area in the global healthcare market. That
growth has been partly driven by cost-containment in several national healthcare sectors,
with governments seeking to promote the use of generic products over higher-priced
originator products. The global generic pharmaceuticals market was worth over $100bn in
2007, with market growth noticeably higher that that of the overall pharmaceutical market.
Our new report - World Generics Market, 2008-2013 - will help you to understand the key
developments in this sector and their significance, from the present looking forward. The
report provides valuable commercial information on this exciting sector, one that no
pharmaceutical company or related organisation can afford to ignore.
Over the period 2008 to 2013, visiongain foresees the generic market to sustain its strong
current growth, with exciting new developments to be driven by the wave of blockbuster
drugs approaching patent expiry. This report - World Generics Market, 2008-2013 -
provides details of these drugs and potential generics revenues. The study also identifies
the therapeutic areas that will face the highest levels of competition from generic
substitutes from 2008 to 2013. Our report examines the global generics market and
industry critically, with in-depth analysis, especially market forecasting and qualitative
analysis of market drivers and restraints. The result is a comprehensive market-based
report with detailed analysis and informed opinion.
Why you should buy this report

In particular, World Generics Market, 2008-2013 concentrates on the following essential
aspects of the generics market and industry:
• Discussion of key issues affecting the global generics market and the wider
pharmaceutical market/industry
• Why governments and healthcare organisations - including private insurers - are
increasingly opting for generic medicines; we provide country-specific information there
• Discussion of drivers and opportunities in the generics sector
• Discussion of restraints and threats in the generics sector
• Sales forecasts from 2008-2013 for the global generics market and leading national
generics markets - US, Japan, Germany, France, UK, Spain, Italy
• Discussion of developing generics markets, especially China, India and Russia, with
major industrial developments covered.
Despite the potentially great opportunities to be harnessed by generics companies in both

developed and developing countries, there remain marked obstacles to be overcome. While
many generics companies are becoming larger and more innovative, originator drugs
companies - especially top-10 pharma companies - are generally prepared for the threat
from generics, having developed strategies to minimise the effects of sales erosion. Still,
there are large potential losses in sales occurring currently - and likely to continue in the
years ahead - as one blockbuster drug after another faces direct and indirect generic
competition.
Certainly, the commercial opportunities for dynamic generics companies are great.
Similarly, the cost-saving opportunities for both public and private healthcare providers
worldwide are significant. By purchasing this report, you will be better able to appreciate
those major developments in the global pharmaceutical market, with many stakeholders
affected.
...more details
The Global Pain Market, 2008-2023

The global pain market generated total sales of $34bn in 2007 – but what will the figures
be in the next 5 and 10 years? This report tells you.
Report Details
The global pain market generated total sales of $34bn in 2007 – but what will the figures
be in the next 5 and 10 years? This report tells you.
The pain market has marked strengths and advantages, but is also limited by problems and
concerns. The market will be driven by new drugs and reformulations of existing ones –
but which drugs will be most successful? The incidence of pain is increasing rapidly, what
some experts call a pain epidemic – so the opportunities available to an additional
blockbuster drug is significant. The prevention and treatment of pain is already one of the
highest priorities for healthcare authorities in the world, yet for mature markets pain drug
sales have fallen. However, visiongain believes that this market has strong growth
potential, despite the prospect of generic competition for leading branded products.
The pain market contained four blockbuster drugs in 2007. Visiongain predicts that there
will be room for more blockbuster drugs in that market segment during the years ahead as
new products are launched, replacing older products. There is great potential for treatments
with greater safety, efficacy and tolerability. This report - The Global Pain Market, 2008-
2023 - provides analysis and forecasts for the overall pain market and its principal
subdivisions, as well as for leading products within those categories. This study also
highlights promising pipeline developments and important contemporary issues, especially
commercial drivers and restraints.
In particular, The Global Pain Market, 2008-2023 analyses global markets for the
following groups of pain treatment:
• Non-narcotics
• Narcotics
• Anti-arthritic treatments
• Anti-migraine treatments.
This report delivers:

• Key analysis split by region and class
• Future market analysis right through to 2023
• Analysis of key brands, generics, strategies in-place today and future strategies over the
next 15 years
• Analysis of key players in the pain market, current and future licensing strategies
This report examines the global pain drug market critically through a comprehensive
review of available information. Sources used include internal databases, industrial
databases, commercial news, company reports, published reports and economic research.
Visiongain applies in-house financial forecasting, qualitative analyses and the assessment
of unmet needs to provide a comprehensive market report with detailed analysis and
informed opinion.
In particular, The Global Pain Market, 2008-2023 concentrates on the following essential
aspects of the market:
• Forecast for the worldwide pain pharmaceutical market from 2008 to 2023
• Forecasts for the principal submarkets from 2008 to 2023
• Commercial prospects for the market-leading drugs, with sales forecasts from 2008 to
2023
• Drivers and restraints in the pain market
• Opportunities and threats in the pain market
• Future therapies that will drive growth in this market
• Pipeline developments with significant commercial potential
• Currently marketed drugs with blockbuster potential
• Discussion of unmet therapeutic needs and relative advantages of products.

• To receive a comprehensive analysis of the prospects for pain drugs from 2008 to 2023
• To discover predicted revenues, growth rates and other key metrics for leading pain
treatments from 2008 to 2023
• To discover “hot” pipeline developments and up-and-coming products
• To determine the forces that influence the market for pain drugs:
• Competitive characteristics of the market
• Drivers
• Restraints
• Strengths, weaknesses, opportunities and threats in that market
• To find out where the market is heading - both technologically and commercially – from
2008 onwards.
...more details
The Global Anti-Addiction Market, 2008-2023

The global addiction market is significantly undervalued. The world's population has a
large unmet need for addiction therapy drugs. Are you ready for the opportunities this
presents? The brand new report, The Global Anti-Addiction Market, 2008-2023, provides
an in-depth analysis of the current state of the market for addiction therapy drugs, from the
present looking forward.
Report Details
The global addiction market is significantly undervalued. The world’s population has a
large unmet need for addiction therapy drugs. Are you ready for the opportunities this
presents? The brand new report, The Global Anti-Addiction Market, 2008-2023, provides
an in-depth analysis of the current state of the market for addiction therapy drugs, from the
present looking forward. It covers the major therapy areas of smoking cessation, obesity,
drug addiction and alcohol dependency. In addition, this study forecasts how your market
will grow and develop, both quantitatively and qualitatively, during the period 2008-2023.
The Global Anti-Addiction Market, 2008-2023, uses a variety of primary and secondary
research methods, including:
• Exclusive visiongain interviews with key opinion leaders in the addiction industry
• Examination of a wealth of secondary sources, including company reports, filings,
analyst presentations and press releases
• Use of in-house and commercial sales databases.
Addiction rates are increasing, yet there is a relative lack of widely-efficacious drugs. Also,
relatively few patients are treated and patient compliance is low for those who are treated
at present. Nevertheless, the growth potential market of this market is significant, both in
developed and developing countries. In addition, awareness of the human and healthcare
costs associated with addiction is increasing amongst patients, healthcare practitioners and
legislators. There is a sense of urgency to combat tobacco addiction, alcoholism and
obesity in particular. Consequently, there are marked opportunities for companies
marketing and developing anti-addiction drugs. But by how much will the market grow
and which therapy areas will be the fastest growing? This report answers those questions
and more besides.
Visiongain has applied detailed financial forecasting and analysis of market/industry

drivers and restraints, including SWOT analysis. The resulting comprehensive market-
based report reveals how leading addiction brands, therapy areas and markets will fare
during the period 2008 to 2023. Key features of the addiction drugs of the future and the
hurdles they will have to overcome for commercial success are discussed.
Other highlights of The Global Anti-Addiction Market, 2008-2023 report include:

• Expert opinion from representatives in the anti-addiction drug industry
• Sales forecasts for the global addiction market and for individual obesity, smoking
cessation, drug addiction and alcohol addiction markets, including leading brands,
manufacturers and country markets
stakeholders in the anti-addiction drugs market
• In-depth analysis of the anti-addiction pipeline
• Geographical breakdown of the anti-addiction drugs market
• Analysis of the addiction markets in the US, France and the UK.

• To receive a comprehensive analysis of the prospects for anti-addiction drugs, including
key metrics and predicted revenues, by type of addiction and brand
• To receive forecasts of addiction drug sales, from 2008-2023, in leading country markets,
including China and Mexico
• To read the views of experts in the addiction industry, regarding current and future trends,
opportunities and sales drivers; the report includes full transcripts of interviews
• The report is packed with graphs, charts, figure and tables of analysis and sales forecasts
• To determine the forces that influence the market for anti-addiction drugs: drivers,
restraints, opportunities and competitive factors
• To find out where the addiction market is heading - both technologically and
commercially from 2008 onwards.
The information contained in this report is not available in any other source and is essential
reading for you and your colleagues. By ordering and reading this report you can gain
market advantage on your competitors today. When aligned with your in-house findings we
are confident you will continue to succeed over the next 15 years.
...more details
World Gastrointestinal Disorders Market 2008-2023

The gastrointestinal (GI) disorders market has been one of the largest and most profitable
therapeutic areas in the world pharmaceutical industry. However. the market is now
mature, with well-established treatments now nearing the end of their patent life. So can
you and your company continue to benefit from this market?
Report Details
The gastrointestinal (GI) disorders market has been one of the largest and most profitable
therapeutic areas in the world pharmaceutical industry. With a reported $49.9bn in
revenues in 2007, the GI disorders market competes consistently with cardiovascular
diseases and oncology for the top 3 therapeutic areas in terms of market value. In 2007,
this sector contributed seven blockbuster drugs, four of which ranked among the top 20
highest revenue generating prescription drugs in the world. However. the market is now
mature, with well-established treatments now nearing the end of their patent life. So can
you and your company continue to benefit from this market? Are you in a position to
capture new profitable shares of the market?
There are new developments, with leading products achieving high blockbuster revenues.
A number of these, including the third most lucrative drug label in the world, Nexium, are
due to lose their patent protection within the next 5-8 years. The emergence of biologics for
IBD treatments has slowed the decline of this market considerably, with high value
products for this difficult-to-treat condition. Such products have facilitated a continuing
rise in sales for the GI market. But how long can the biologics stabilise a market that is
experiencing decline in sales of major products, especially due to generic competition?
This informative, fully independent report will tell you. And tell you today!!
The purpose of this market report - World Gastrointestinal Disorders Market 2008-2023 -
is to examine the prospects of the GI market. This report includes sales forecasts for
leading products and submarkets, in addition to the overall GI market. The GI disorders
market is one of the largest and most important in the pharmaceutical industry.
Furthermore, the treatment of GI disorders has a high profile, both among the general
population and in organised healthcare. Importantly, the GI market has recently entered a
crucial phase, with mounting commercial pressures affecting revenue generation and
causing market participants to reconsider strategies. This report outlines how leading
companies are responding to the opportunities, threats and uncertainty.
World Gastrointestinal Disorders Market 2008-2023 examines the GI market critically

through detailed analysis of market leaders and new developments, interviews and
questionaires with industry players, plus commercial databases, company reports and
business/industry news. Visiongain applied unique in-house techniques for financial
forecasting, plus SWOT analysis and the assessment of unmet needs to provide a
comprehensive market report with detailed analyses and informed opinion. In particular,
this report concentrates on the following essential aspects of the GI market:
• The current state of the world market for drugs to treat gastrointestinal disorders
• Drivers and restraints
• Opportunities and threats
• Key industrial players in the GI market
• Revenue trends in the world gastrointestinal market between 2008-2023, including
principal submarkets
• Prospects for leading GI drugs between 2008-2023
• A comprehensive discussion of patent expiry and generic substitution and their
commercial implications
• Analyses of the principal national markets for GI pharmaceuticals
• Discussion of leading pipeline products and line extensions.
• To receive a comprehensive analysis of the prospects for the world gastrointestinal

disorders market from 2008-2023, including sales forecasts, major growth areas and most
talked-about pipeline products
• To discover predicted revenues, growth rates and other key metrics in the world
gastrointestinal disorders market from 2008-2023, especially for leading brands
• To determine the forces that influence the gastrointestinal disorders market:
• Drivers and restraints on market
• Competition
• Strengths, weaknesses, opportunities and threats.
• To find out where the world gastrointestinal disorders market is heading from 2008
onwards, both technologically and commercially.
...more details
The Japanese Pharmaceutical Market 2008-2023

Last year, the Japanese pharmaceutical market was the second largest in the world, with a
value of $58.5bn. However, Japan’s market has experienced growth at a much lower rate
than the other major pharmaceutical markets. It is at a key stage in its development. You
need to take notice of these changes.
Report Details
Last year, the Japanese pharmaceutical market was the second largest in the world, with a
value of $58.5bn. However, Japan’s market has experienced growth at a much lower rate
than the other major pharmaceutical markets. It is at a key stage in its development. You
need to take notice of these changes.
For many years the market has been dominated by the pricing and reimbursement policy of
the Japanese government, which is arguably the most stringent of all the major
governments. A determination to maintain tight cost controls on healthcare in Japan has
resulted in the cost of drugs being tightly controlled. The government imposes limits on the
price of drugs, and these are reduced every two years. This situation has caused concern to
the international pharma industry, which remains eager to make further inroads into that
large market. Are you achieving the success you should in Japan?
It is this imposed price control that is the key determining factor in influencing the shape,
size and potential of the Japanese pharmaceutical market. The Japanese pharmaceutical
market should have greater growth. However, the expansion of that market is influenced by
several factors, including:
• Biennial National Health Insurance drug price reductions
• Increasing R&D expenses
• Intensifying competition between domestic companies and foreign international
pharmaceutical companies, especially market leaders
• Restructuring within the pharmaceutical industry in Japan and worldwide
• Non-availability of many leading international products
• Relatively low use of generics
• A regulatory system that has recently become more accessible to international pharma
companies.
The Japanese pharmaceutical market is at the start of a cycle that will see an increasing
number of mergers and overall consolidation. The extent of the mergers involving a global
pharmaceutical company buying out a smaller Japanese company will depend largely on
the pipeline of the Japanese company involved. Global pharmaceutical companies, such as
Pfizer, are already establishing a major presence in Japan.
The Japanese Pharmaceutical Market 2008-2023 examines that leading market critically,
through a comprehensive review of available information. Sources include in-depth
interviews, primary research, industrial databases, commercial news, in-house reports and
economic research. Visiongain also applied financial forecasting, qualitative analyses and
the assessment of unmet needs to provide a comprehensive market report with detailed
analysis and informed opinion. This information is not available anywhere else.
In particular, this Japanese pharmaceutical market report from visiongain

concentrates on the following essential aspects of that market:
• Discussion of the current Japanese pharmaceutical market in the context of the global
pharma market
• Forecast of the overall Japanese pharmaceutical market from 2008 to 2023
• Drivers and restraints facing the Japanese market
• Opportunities and threats facing the Japanese market
• Commercial prospects for the market-leading drugs, with sales forecasts from 2008 to
2023
• Individual forecasts of the leading drug classes from 2008 to 2023
• The potential of generics manufacturers to penetrate this market
• Relevant pipeline developments with blockbuster potential
• Discussion of unmet therapeutic needs

• To receive a comprehensive analysis of the prospects for the Japanese pharmaceutical
market from 2008 to 2023
pharmaceutical treatments from 2008 to 2023, both by major therapeutic area and leading
products
• To determine prospects of leading companies in that market
• To discover "hot" pipeline developments and up-and-coming products
• To determine the forces that influence the Japanese market: drivers, restraints, strengths,
weaknesses, opportunities and threats
• To find out where the market is heading - both technologically and commercially from
2008 onwards
...more details
Women's Reproductive Disorders Therapeutics 2008-2018

This visiongain report provides a detailed analysis of the market for women's reproductive
health pharmaceutical products. The report discusses current and future products and
market climates for the following areas: - Hormonal contraceptive use - Use of hormone
replacement therapy (HRT) for menopause - Infertility therapeutics.
Report Details
Visiongain predicts that there is great potential for the women’s reproductive disorders
therapeutics market from present onwards, as this new report Women’s Reproductive
Disorders Therapeutics, 2008-2018 shows.
Oral Contraceptive Market

The systemic hormonal contraceptive market is currently a $7bn market, with hormonal
oral contraceptives dominating the market for many years. The oral pills are increasingly
facing competition from other routes of delivery. With patent expiration, several companies
have begun manufacturing generic products. Hormonal contraceptives for women have
become the benchmark for the safety and effectiveness of birth control methods.
Although hormonal contraceptives are already a very mature market, visiongain believes
that there is still room for further growth. In addition, modern basic research has identified
some completely new approaches for the contraceptives of the future. Hormonal oral
contraceptives will continue to play an important role in birth control from 2008 to 2018.
Lifecycle Management and Product Line Extension

The hormonal oral contraceptive market is undergoing both lifecycle management and
product line extension of existing products in the market. There are progestin-only
preparations and combined preparations containing an oestrogen and a progestin. Bayer
Schering is developing a pill containing various forms of progestin. Clinical studies show
that the new drospirenone pill has an apparent therapeutic effect on premenstrual dysphoria
- a particularly severe form of the premenstrual syndrome (PMS), as well as on acne. Pills
are increasingly being developed with reduced oestrogen dosages. Visiongain evaluates the
prospects for extended or continuous administration of oral contraceptives. It is becoming
popular for the treatment of endometriosis, dysmenorrhoea and menstrual-associated
symptoms.
Menopause and Hormone Replacement Therapy

HRT has been the subject of considerable discussion recently. In light of recent and current
studies, visiongain provides comprehensive market information on HRT market prospects
from 2008 to 2018.
Women’s Reproductive Disorders Therapeutics, 2008-2018 examines that market critically,

through comprehensive primary and secondary research. In addition to consultation with
industry opinion, this research involved a detailed study of policy documents, industrial
reports and relevant news. Importantly, visiongain also applied techniques such as financial
forecasting, SWOT analyses and qualitative projections. The result is a comprehensive
market-based study with detailed financial analyses and informed opinion on the future of
the women’s reproductive health market.
In particular, our new Women’s Reproductive Disorders Therapeutics, 2008-2018

report concentrates on the following essential aspects of that market:
• Overview of the women’s reproductive therapies market
• Key industrial players in the global women’s reproductive therapies market
• Forecasts of global market from 2008-2018, including forecasts of the leading therapeutic
agents in this market area
• Forecasts for therapies in the seven leading pharmaceutical markets
• Drivers and opportunities in the global women’s reproductive therapies market
• Restraints and threats in the global women’s reproductive therapies market
• Primary research, with full interview transcripts
• Coverage of pipeline developments, with discussion of trends from the present onwards
Why You Should Buy This Report

In Women’s Reproductive Disorders Therapeutics, 2008-2018 you will receive the
following essential information for understanding the women’s reproductive disorders
therapeutics market and industry:
• The value of the women’s reproductive disorders therapeutics market and its principal
market segments from 2008 to 2018
• Which current or future therapies that will drive the market for women’s reproductive
disorders therapeutics from 2008 to 2018, with detailed sales forecasts
• Market drivers and restraints, including a comprehensive SWOT analysis for women’s
reproductive disorders therapeutics
• The companies involved in the market and their business strategies
This Report would be Useful to the Following Professionals, Amongst Others:

• Business managers of pharmaceutical industry related to women’s reproductive disorders
therapeutics
• Researchers, analysts and academics interested in women’s reproductive disorders
therapeutics
• Senior staff in healthcare authorities relevant to women’s reproductive disorders
therapeutics
• Investors in the pharmaceutical industry relevant to women’s reproductive disorders
therapeutics
• Other interested business managers of multinational companies relevant to women’s
reproductive disorders therapeutics
• Other business managers of domestic companies
• Academics, researchers and media
...more details
Global Antivirals Market Analysis & Forecasts 2008-2023

Investors are turning their attention to antiviral drug discovery because there is a renewed
recognition of the promising opportunities in this $20bn market. Twenty years from the
inception of focused antiviral drug research, there are 8 blockbuster drugs currently on the
market.
Report Details
Investors are turning their attention to antiviral drug discovery because there is a renewed
recognition of the promising opportunities in this $20bn market. Twenty years from the
inception of focused antiviral drug research, there are 8 blockbuster drugs currently on the
market. Its double-digit growth makes it a standout segment within the general anti-
infective therapeutic class. You should be maximizing your opportunities in this market.
The opportunities for success are there now, you should capitalize on them immediately.
The key driver of the market is the rapid development of resistance to existing therapies by
the evolving viruses. The constant need to update the pipeline fuels your investigative and
commercial interest in this market – so you must act on this today. This report - Global
Antivirals Market, 2008-2023 - analyses the global antiviral market comprehensively,
outlining where you should aim your future developments to guarantee success. The
analyses tackle different aspects of the market, including the leading therapeutic classes,
leading antiviral products, key industrial players as partners and financial prospects and
opportunities. The report also delivers in-depth predictions concerning how the market
will develop from present until 2023.
Global Antivirals Market, 2008-2023 examines the market for antivirals critically, through
comprehensive primary and secondary research. In addition to consultation with experts in
the industry, this research involved a detailed study of policy documents, industrial reports
and relevant news. Essentially, visiongain also applied unique in-house techniques such as
our developed financial forecasting, SWOT analyses and qualitative projections which are
unavailable elsewhere. The result is a comprehensive market-focused study with detailed
financial analyses and uniquely informed opinion on the future of the antivirals market.
In particular, our new Global Antivirals Market 2008-2023 report concentrates on the
• Antiviral drugs assessment and opportunities
• Key industrial players in the global antivirals market
• Forecasts of global antivirals market from 2008-2023, including in-house developed
forecasts of the leading therapeutic agents
• Forecasts for the antiviral therapies in the seven leading developed pharmaceutical
country markets and two leading developing markets
• Drivers and opportunities in the global antivirals market
• Restraints and threats in the global antivirals market
• Key opinion from relevant experts - full interview transcripts are included with the report
(unavailable anywhere else)
• Coverage of pipeline developments in the antivirals market, with discussion of trends
from the present onwards

• To receive a comprehensive analysis of the prospects for the antivirals industry from
2008-2023, including sales forecasts, major growth areas and most exciting pipeline
developments
• To discover predicted revenues, growth rates and other key metrics in the global
antivirals market from 2008-2023, with leading brands and principal market segments
covered
• To determine the forces that influence the global antivirals market:
• Drivers and restraints on that market
• Competition
• To find out where the global antivirals market is heading from 2008 onwards - both
The information contained in this report is not available in any other source and is essential
reading for you and your colleagues. By ordering and reading this report you can gain
market advantage on your competitors today. When aligned with your in-house findings we
are confident you will continue to succeed over the next 15 years.
...more details
The Global Vaccines Market 2008-2023
The key growth driver for vaccines is their cost-effectiveness in combating disease. This
situation will encourage greater use of vaccines by governments and private healthcare
providers. New disease targets that could be mitigated through vaccination, including high
profile (and potentially profitable) targets such as cancer.
Report Details
The period 2008-2023 will see a vaccine “boost”. There will be a new resurgence in the
sales and utilisation of vaccines. Are you prepared for this? You should be.
During this period, vaccines will be one of the fastest growing segments of the
pharmaceutical market. Vaccine revenues will increase in size by several hundred percent
between 2007 and 2023. This brand new in-depth report The Global Vaccines Market,
2008-2023 describes trends in the market both quantitatively and qualitatively. In recent
years, this global vaccines market has undergone a renaissance, as the importance of
vaccines in both developed and developing nations becomes underlined by epidemiological
patterns and healthcare needs.
The key growth driver for vaccines is their cost-effectiveness in combating disease. This
situation will encourage greater use of vaccines by governments and private healthcare
providers. New disease targets that could be mitigated through vaccination, including high
profile (and potentially profitable) targets such as cancer. Visiongain notes that many
healthcare providers are viewing preventative medicine enthusiastically, being aware of the
significant increases in quality of life and reduction of healthcare expenditure that can
result from prophylaxis. The vaccines industry is responding with innovative products,
making full use of technological advances in biotechnology. This market has great
developmental potential, both therapeutically and commercially. There are currently more
than 1000 vaccines in research and development worldwide.
In particular, The Global Vaccines Market, 2008-2023 concentrates on the following

essential aspects of the vaccine industry:
• Sales forecasts for vaccines by disease area, brand and country, including novel
therapeutic vaccines
• Examination of strengths, weakness, opportunities and threats facing the vaccine industry
• Expert opinion from key-opinion leaders in the field
• In-depth analysis of the vaccine pipeline
• Analysis of the prospects for therapeutic vaccines
• Geographical breakdown of the vaccine market, including the leading emerging markets
of China and India
• Coverage of future trends in vaccine technology, formulation and manufacturing
• Identification of key industrial players in the vaccines market.
The Global Vaccines Market, 2008-2023 examines the vaccines market comprehensively,
using unique primary and secondary research. The report includes full transcripts of
interview – you cannot get this information anywhere else.
Also included are company reports, filings and industry databases. Exclusively, visiongain
have applied their in-house analytical techniques for financial forecasting and analysis of
drivers and restraints. Now available to you this comprehensive market-based report with
detailed analyses, forecasts and informed opinion is essential to your vaccine market
development.
Therapeutic vaccines differ from currently-marketed vaccines. Instead of simply

preventing infection from disease, therapeutic vaccines work with the body’s immune
system to fight diseases and disorders, including cancer, addiction and allergies. Their
therapeutic and commercial potential is vast. Visiongain predicts that therapeutic vaccines
will significantly expand the market for vaccines, contributing to rapid revenue growth
during the period 2008 to 2023.

• To receive a comprehensive analysis of the prospects for vaccines, including key metrics
and predicted revenues, by vaccine disease area and leading brand
• To receive forecasts of vaccine sales in leading country markets from 2008-2023,
including China and India
• To discover the views of experts in the vaccines sector
• To determine the forces that influence the market for vaccines: drivers, restraints,
opportunities and threats
• To find out where the vaccines market is heading - both technologically and
commercially from 2008 to 2023.
...more details
Global Biotech Market Analysis and Forecasts, 2008-2023

experienced great expansion since its emergence during the 1970s.
Report Details
- Includes Top 10 Therapy classes for biotech

- Also Top 10 products in the biotech sector
experienced great expansion since its emergence during the 1970’s. The leading
biotechnology company, Amgen, is now amongst the largest pharmaceutical companies in
the world, with other biotechnology companies catching up. The global biotech drug
market was worth over $75bn in 2007, with double-figure growth noticeably higher that
that of the overall pharmaceutical market.
Over the period from 2008 to 2023, visiongain expects the healthcare biotechnological
market to continue its strong growth, with exciting new developments both technologically
and commercially. Increased R&D efforts, shorter approval times and innovative new
treatments are aiding market growth. However, the two major threats the healthcare
biotechnology sector faces in the coming years are the increasing threat of biogenerics and
the difficulty in acquiring capital. Strategic partnerships will continue to be important to
biotechnological drug development.
This brand new report - Global Biotech Market, 2008-2023- examines the healthcare
biotech market critically, through comprehensive research and analysis. This report covers
both the top ten therapy classes as well as the top ten leading pharmaceutical products in
the biotech market in particular, as well as leading pipeline agents. Furthermore, visiongain
applied techniques such as their in-house financial forecasting technology, SWOT
analyses, R&D pipeline analysis and qualitative projections. The result is a comprehensive
market-based report with detailed analysis and informed opinion.
You will not find this information available anywhere else.

In particular, our Global Biotech Market, 2008-2023 report concentrates on the following
essential aspects of that market, including the competitive environment for original
branded products and biogenerics:
• Detailed analysis of the global biotech market, including an overall market sales forecast
for 2008-2013, 2018 and 2023
• Sales forecasts for leading products and therapeutic areas for 2008-2013, 2018 and 2023
• Discussions of issues affecting the market segments, including SWOT analysis
• Drivers and opportunities in the biotech industry
• Restraints and threats facing the biotech industry
• Discussion of the leading companies and their strategy in the context of the market
• Pipeline developments and their implications for the future
• Strategic alliances and licensing.
There are significant financial benefits from a company’s having a portfolio of biotech
drugs, especially in this very uncertain period, when technological and commercial change
is accelerating. This realisation has caused the major pharmaceutical companies to
establish themselves in the biotech market. At least half of the top ten pharmaceutical
companies now have leading biotech drugs. Thinning developmental pipelines in small
molecule agents can, in part, explain big pharma's embracing of the biotech market, forcing
them to buy biotech firms with promising drugs in development. This report provides
valuable commercial information on this exciting industry that no healthcare company
should ignore.
...more details
Contract Pharma 2008-2023

The revenue for world contract manufacturing business in 2007 was approximately $30bn,
with a growth rate of 6% from 2006. The technical expertise and cost savings offered by
contract manufacturing organisations (CMOs) make them increasingly essential to you and
your organisation.
Report Details
The revenue for world contract manufacturing business in 2007 was approximately $30bn,
with a growth rate of 6% from 2006. The technical expertise and cost savings offered by
contract manufacturing organisations (CMOs) make them increasingly essential to you and
your organisation. Greater emphasis has been put on European CMOs to leverage low-cost
contract manufacturing markets, such as those existing in India and China, to enhance cost
efficiency. Many CMOs in Europe have turned to biotech services as a means of avoiding
competition with lower-cost API companies based in developing countries. In common
with European service providers, North American CMOs are adopting a dynamic
approach. Also, they are providing other services, such as packaging, logistics and
marketing support. Are you taking advantage of the opportunities available? This unique
report will guide you and inform you on how to benefit from the options - you should take
the opportunity today.
Recent years have seen the emergence of moderate level competition from Indian and
Chinese CMOs. This new visiongain report - Contract Pharma 2008-2023 - evaluates the
prospects for outsourcing manufacturing and other operations from pharmaceutical
companies, especially off-shoring to developing nations such as China and India.
Furthermore, this report analyses the increasing trend for Japan to outsource services
abroad.
In particular, the following factors have been highlighted in this report:

• Synchronization of regulations
• Mutual recognition of GMP documentation
• Improved information exchange.

In Contract Pharma 2008-2023 you will receive the following essential information for
understanding the contract pharma market:
- The value of the contract pharma business market and its principal market segments from
2008 to 2023, with detailed forecasts and growth analyses
- Market drivers and restraints, including a comprehensive SWOT analysis
- Comprehensive views of key opinion leaders on contract pharma, including leading
companies, with full interview transcripts from our in-depth survey worldwide
- The companies involved in contract pharma business and their business strategy
- The present state of contract pharma business and future trends there
- What contract pharma opportunities exist for market entrants, both established companies
and newcomers
- The main concerns for outsourcing clinical trials to CROs
- Changes in contract pharma regulations
- CMOs are increasingly undertaking analytical testing and other value-added services
alongside traditional contract manufacturing of APIs. In some major CMOs, these value-
added services have taken up significant proportion of their revenue generation. This rate
will increase further in the coming decade. The establishment of large, global companies
offering a full range of contract services has led to a change in the image of CROs and
CMOs. There has been a shift in the business model of CMOs to integrate themselves more
fully into the supply chain of pharmaceutical and biopharmaceutical companies by offering
a wider range of services.
The report is intended for the following professionals, amongst others:

- Directors, business development managers and researchers of pharmaceutical and
biopharmaceutical companies worldwide
- Directors, business development managers and researchers in the healthcare industry
- Policy makers, researchers, analysts and academic researchers
...more details
Osteoporosis & Bone Metabolism Disorders Market 2008-2023 Management Report

In 2007, the world market for bone metabolism disorder pharmaceuticals generated sales
of over $10bn - how much of this market have you captured?
Report Details
In 2007, the world market for bone metabolism disorder pharmaceuticals generated sales
of over $10bn - how much of this market have you captured?
The majority of this market consists of the fast-expanding osteoporosis segment, a disease
with high incidence and under-treatment at present. The bone metabolism market is
competitive and progressive, facing generic competition amongst its top-selling drugs.
Nevertheless, market growth will be driven by aging populations worldwide and the entry
of novel therapies during the years ahead. In Osteoporosis & Bone Metabolism Disorders,
2008-2023, visiongain forecasts that the bone metabolism disorder market will increase -
but by just how much? Order the report today to find out..
Worldwide, significant numbers of osteoporosis sufferers remain undiagnosed. Amongst
those taking medication, patient compliance is poor. In addition, bone metabolism disease
patients have significant unmet needs. All these factors provide additional opportunities for
further growth in the market. During this growth period, there will be major changes in the
nature and make-up of the bone metabolism disorder market. This will include the decline
in bisphosphonate drugs and the emergence of novel therapies.
This visiongain report reviews the global bone metabolism disorder market in detail
thorough comprehensive forecasting and other analysis, as well as interviews with experts
in the field, including KOLs in industry. In particular, Osteoporosis & Bone Metabolism
Disorders, 2008-2023 concentrates on the following essential aspects of the global
osteoporosis and bone metabolism market:
• Financial forecasts covering the period 2008-2023, including leading brands, companies,
country markets and therapeutic classes of drug
• Expert opinion from industry sources
• Identification of key drugs in a well-stocked bone metabolism disorder pipeline
• Key industrial players – established and emerging - in the bone metabolism market
• Geographical breakdown of the market, including sales forecasts for leading markets,
including China and India

• To receive a comprehensive analysis of the prospects for the osteoporosis and bone
metabolism industry from 2008-2023, including sales forecasts, major growth areas and
most talked-about pipeline products
• To discover predicted revenues, growth rates and other key metrics for bone disorder
drugs from 2008-2023, especially leading brands
• To determine the forces that influence the osteoporosis and bone metabolism market:
• Competition
• To find out where the bone metabolism market is heading from 2008 onwards - both
...more details
Pfizer - Market Outlook for a Global Leader, 2008-2013

Pfizer is the world's largest and most profitable pharmaceutical company. Its
pharmaceutical division generates sales of $44671m in 2007. Pfizer is recognised as being
one of the strongest performing pharmaceutical companies in terms of sales, revenue
growth, acquisitions, breadth of portfolio, product launches and pipeline developments.
Report Details
Pfizer is the world's largest and most profitable pharmaceutical company. Its
pharmaceutical division generates sales of $44671m in 2007. Pfizer is recognised as being
one of the strongest performing pharmaceutical companies in terms of sales, revenue
growth, acquisitions, breadth of portfolio, product launches and pipeline developments.
Pfizer's prominence is due to the company having nine blockbuster products, seven market
leaders and strong products in all the major therapeutic categories. How can you compete
with them? Which areas are the exposed in? Find out today.
This new report - Pfizer - Market Outlook for a Global Leader, 2008-2013 - examines the
Pfizer group critically, through comprehensive research and analysis. This report covers
both of Pfizer’s pharmaceutical and animal healthcare division. Importantly, visiongain
discusses Pfizer in the context of the wider pharmaceutical industry and global market.
Furthermore, visiongain applied independent analysis and techniques such as financial
forecasting, SWOT analyses, R&D pipeline analysis and qualitative projections. The result
is a comprehensive market-based report with detailed analysis and informed opinion.

In particular, Pfizer - Market Outlook for a Global Leader, 2008-2013 concentrates on the
following essential aspects of that company and it s market, including the competitive
environment for leading pharma companies:
• Detailed analysis of Pfizer’s divisions and its products, including Lipitor
• Sales forecasts for Pfizer’s pharmaceutical division
• Sales forecasts for key products and therapeutic areas
• Discussions of issues affecting the relevant market segments, including competitor
analysis
• Drivers and opportunities for Pfizer
• Restraints and threats facing the company
• Discussion of company strategy in the context of the market
• Pipeline developments and their implications for the future
• Strategic alliances and licensing
• International operations, including developing markets.
Visiongain believes that the period 2008 to 2013 will be pivotal for Pfizer, particularly due
to patent expiry and the demands of new technological paradigms, such as biologics and
genomic medicine. A closer examination of Pfizer’s portfolio reveals that many of its
leading products will lose patent protection during the next five years, causing severe
revenue erosion for the company.
Those challenges include Lipitor, the number-one selling drug in history and a product
responsible for a significant share of Pfizer's revenue. The global healthcare industry is
entering an exciting new period, with both significant opportunities and great challenges
for companies such as Pfizer. Any professional interested in the fortunes of leading
pharmaceutical companies from the present onwards cannot afford to ignore this study.
Therapeutic Monoclonal Antibodies Report 2008-2023
This brand new report investigates the global market for therapeutic monoclonal
antibodies. While the pharmaceutical industry as a whole is suffering from single digit
growth, thinner pipelines than before and pressure from an ever-aggressive generics
industry, the segment of monoclonal antibodies therapeutics is thriving and growing at a
double-digit rate.
Report Details
This brand new report investigates the global market for therapeutic monoclonal
antibodies. While the pharmaceutical industry as a whole is suffering from single digit
growth, thinner pipelines than before and pressure from an ever-aggressive generics
industry, the segment of monoclonal antibodies therapeutics is thriving and growing at a
double-digit rate. Therapeutic Monoclonal Antibodies 2008-2023 shows how monoclonal
antibodies are a leading product of biotechnology, being increasingly used in therapy.
Currently, monoclonal antibodies are playing an important role in the treatment of cancer,
autoimmune and inflammatory disorders. Therapeutic monoclonal antibodies boast one of
the most active and promising pipelines in the pharmaceutical industry.
Ten years ago, there were only two monoclonal antibody drugs on the world market, now
there are 21 FDA approved therapies – including eight blockbuster drugs. In 2007, the
market was worth $21.9bn, but what will it be in 5 years time? This report will tell you and
tell you today. Visiongain believes that some of the greatest opportunities ever available for
biopharmaceutical companies are now there to be seized, with important sales, licensing
agreements and collaborative partnerships from the present onwards in monoclonal
antibodies and other biologicals.
Our new Therapeutic Monoclonal Antibodies 2008-2023 report examines the market for
monoclonal antibodies critically, through comprehensive primary and secondary research.
In addition to consultation with experts in industry - including full interview transcripts -
this research involved a detailed study of relevant documents, industrial reports and current
developments. Visiongain discusses the monoclonal antibody market in the context of the
biotechnological platforms and therapeutic areas. Importantly, visiongain applied
techniques such as financial forecasting and analysis of drivers and restraints. The result is
a comprehensive market-based report with detailed analyses and informed opinion.
In particular, Therapeutic Monoclonal Antibodies 2008-2023 concentrates on the following

essential aspects of the monoclonal antibodies sector:
• Technologies that drive the MAb sector
• Therapy areas that drive the MAb sector
• Sales forecasts of the global therapeutic MAb market from 2008-2023 - including those
of principal market segments, both by disease area and technology
• Sales forecasts for leading products worldwide in this sector
• Sales forecasts for therapeutic MAb sales in leading national markets, including China
and India
• Key industrial players in the therapeutic monoclonal antibody sector - both established
and emerging – including partnerships
• Drivers and opportunities in the MAb sector
• Restraints and threats in the MAb sector
• Assessments of relevant business models, technological solutions and associated issues
• Coverage of future trends in MAbs, especially pipeline developments
• Insight from interviews with relevant experts

• To receive a comprehensive analysis of the prospects for the therapeutic monoclonal
antibodies industry from 2008-2023, including sales forecasts, major growth areas and
pipeline products
• To discover predicted revenues, growth rates and other key metrics in the therapeutic
monoclonal antibodies market from 2008-2023, especially for leading brands
• To determine the forces that influence the therapeutic monoclonal antibodies market:
• Competition
• To find out where the therapeutic monoclonal antibodies market is heading from 2008
onwards - both technologically and commercially
...more details
Global Clinical Trial Business Report & Analysis 2008-2018

The global clinical trials business is worth an estimated $50bn in 2008, with a growth of
rate of 10%. The market will show considerable growth in the future, as this visiongain
report, Global Clinical Trial Business 2008-2018, explains in detail. In recent years, the
nature of clinical trials has changed considerably.
Report Details
The global clinical trials business is worth an estimated $50bn in 2008, with a growth of
rate of 10%. The market will show considerable growth in the future, as this visiongain
report, Global Clinical Trial Business 2008-2018, explains in detail. In recent years, the
nature of clinical trials has changed considerably. An increased emphasis has been placed
on cost-effectiveness of pharmaceutical R&D, as well as increased productivity to maintain
the high output of recent years. Consequently, the pharmaceutical industry has witnessed
rapid expansion of outsourced clinical services in both the West and in developing nations,
most notably India and China. Importantly, pharmaceutical and biotechnological
companies are increasingly delegating the responsibility of clinical trials to contract
research organisations (CROs).
This visiongain report investigates the global market for such services, providing forecasts
for revenues and expenditure there, as well as a comprehensive examination of principles
driving and restraining the clinical trials market worldwide. Neither pharmaceutical
companies nor CROs can afford to ignore this research, which relies heavily upon
interviews with experts in the relevant sectors, as well as providing comprehensive revenue
forecasts for the next 10 years.
The majority of the revenues generated by the clinical trials industry are due to large
pharmaceutical companies outsourcing clinical research, the most crucial and expensive
stage of drug development, to companies specialising in that work. The major challenge for
the pharmaceutical companies in the next five years will be to maintain high growth rates.
The branded pharmaceuticals market is under substantial pressure due to:
• Existing generic competition

• Impending loss of major patents
• Relatively thin pipeline.
Because of the nature of the clinical trials industry it will, in turn, experience increasing
pressures to deliver a cost-effective service. The demand among drugs companies for a
more cost-efficient pipeline has therefore intensified in recent years. The strategy that
pharmaceutical companies now seem to be applying to clinical trials mirrors the latest
trends in the drug discovery section of development.
Contract research organisations (CROs) are playing increasingly vital roles on behalf of
manufacturers in the global drug development process, from conducting Phase I trials to
post-marketing studies. It is often difficult for pharmaceutical and biotech companies to
decide which CRO to offer a contract to. However, the market is due to undergo rapid
change over the coming years, with different companies approaching the challenges in
different ways. The CRO market, however, continues to grow steadily at an average 10%
yearly growth rate. Visiongain predicts that there remains a sufficient growth opportunity
for both mainstream and other CROs.
Why You Should Buy This Report:

In Global Clinical Trial Business 2008-2018 you will receive the following essential
information for understanding the clinical trial business:
• The value of the clinical trial business market and its principal market segments from
2008 to 2018
• Which current or future therapies that will drive the market for clinical trial business from
2008 to 2018
• Market drivers and restraints, including a comprehensive SWOT analysis
• Comprehensive views of key opinion leaders on clinical trial business
• The companies involved in clinical trial business and their business strategy
• Forecasts for revenue in each of the phases of clinical trial business
• The present state of clinical trial business and future trends there
• What contract research opportunities exist for market entrants, both established
companies and newcomers
• The main concerns for outsourcing clinical trials to CROs
• Ways to improve cost-effectiveness of clinical trial business
• Changes in clinical trial regulations
• Focus on drug safety issues.
Clinical trials are now performed in many regions of the world, with increasing numbers of
major pharmaceutical and biotechnology companies performing or outsourcing clinical
trials in rapidly developing nations such as India and China.
Visiongain’s Global Clinical Trial Business 2008-2018 report also covers the following
issues:
• Electronic data capture (EDC) systems have existed for approx. 20 years and pharma
companies are beginning to recognise the value of those processes in clinical research.
• Adaptive clinical trials are a concept in development: adaptive trial designs have the
potential to benefit drug development programmes, changing current processes
• Biomarkers can increase efficiency of clinical trials by identifying potential failures early,
saving time and money potentially, facilitating drug development and paving the way to
more-personalised medicine with better safety and efficacy profiles, especially in defined
populations.
This Report is essential to the Following Professionals, Amongst Others:

• Investors in clinical trial business
• Business managers of multinational companies in both the developed and developing
countries
• Business managers of domestic companies in the emerging economies
• Business managers of pharmaceutical industry related to outsourcing
• Researchers, analysts and academics interested in clinical trial business
• Senior staff in healthcare authorities relevant to clinical trial business.
...more details
Oncology Market Leaders - Analyses and Outlook, Market Report 2008-2023

The UK government have told kidney cancer patients that new drugs cannot be offered on
the National Health Service. Roche's Avastin, Bayer's Nexavar, Pfizer's Sutent and Wyeth's
Torisel were not cost-effective. The drugs -- known generically as bevacizumab, sorafenib,
sunitinib and temsirolimus -- should therefore not be a treatment option for advanced
and/or metastatic kidney cancer, NICE said.
Report Details
The UK government have told kidney cancer patients that new drugs cannot be offered on
the National Health Service. Roche's Avastin, Bayer's Nexavar, Pfizer's Sutent and Wyeth's
Torisel were not cost-effective. The drugs -- known generically as bevacizumab, sorafenib,
sunitinib and temsirolimus -- should therefore not be a treatment option for advanced
and/or metastatic kidney cancer, NICE said.
Cancer Research UK said it raised questions about whether NICE's system of appraisal
was appropriate for all types of drugs, especially when there were few alternative
treatments. NICE argues it has to make tough choices when deciding which drugs should
be paid for and which not.
Modern targeted drugs are revolutionising cancer care, yet they often increase survival by
only a few months. Drug companies argue they need to charge a high price for them to
make a return on risky research investment. The high price of treatment with the kidney
drugs means it would cost GBP71,500 to GBP171,300 ($139,800-335,000) for every year
of healthy life gained, NICE calculated.
Today there are an estimated 24.6 million people in the world living with cancer. The
World Health Organisation (WHO) has predicted that the worldwide incidence will rise by
50% between 2000 and 2020. Cancer is becoming increasingly common in developing and
developed countries, with significant potential for market expansion in both regions.
Worldwide, there remain significant unmet needs in cancer treatment, with great
opportunities for companies who can develop safer and better-targeted treatments. Our new
report Oncology Market Leaders - Analyses and Outlook, 2008-2023, will help you to
understand those developments and their significance.
According to IMS, sales data for 2007, the oncology area ranked as the fifth-largest
therapeutic class worldwide. In 2007, the anti-cancer drug market generated sales of
$66.8bn, up by 17% in comparison with $57bn in 2006. MabThera/Rituxan, Herceptin and
Avastin - leading products of biotechnology and pharmacogenomics – are currently
amongst the most prominent drugs in cancer therapy. Furthermore, the cancer pipeline
remains strong. Current and future R&D is likely to produce significant therapeutic
advances, especially when combined with pharmacogenomic medicine, particularly
theranostics.
Oncology Market Leaders - Analyses and Outlook, 2008-2023, examines the product
portfolios of the leading companies in oncology critically, with in-depth analysis,
especially market forecasting and qualitative analyses of market drivers and restraints. This
report also contains primary research from our survey of experts in the field. The result is a
comprehensive market-based report with detailed analyses and informed opinion.

In particular, this report concentrates on the following essential aspects of that market:
• Detailed analysis of the current oncology market – achievements and present challenges
• Sales forecasts for the oncology market from 2008-2023
• Sales forecasts for the leading 10 drugs in that market from 2008-2023
In Vitro Diagnostics Market Report & Analysis 2008-2023
Technological solutions are playing an increasingly important role in both clinical practice
and pharmaceutical R&D - increasing safety, speeding up clinical development and
facilitating regulatory acceptance. Furthermore, current developments in diagnostics -
especially molecular diagnostics - are paving the way towards the long-held goal of
personalised medicine, to the benefit of patients, companies and healthcare providers.
Report Details
This brand new report examines the commercial prospects for in vitro diagnostics (IVD) in
the global healthcare market. Technological solutions are playing an increasingly important
role in both clinical practice and pharmaceutical R&D - increasing safety, speeding up
clinical development and facilitating regulatory acceptance. Furthermore, current
developments in diagnostics – especially molecular diagnostics - are paving the way
towards the long-held goal of personalised medicine, to the benefit of patients, companies
and healthcare providers. Developments in IVD also receive encouraging support from
regulators such as the FDA. Visiongain believes that some of the greatest opportunities
ever available for diagnostics companies are now there to be seized, with important sales,
licensing and partnership developments from the present onwards.
Importantly, this report also covers theranostics, a fusion of drug therapy and diagnostics to
optimise efficacy and safety, as well as streamlining drug development. Combining a drug
with a diagnostic process or test is also known as companion diagnostics, integrated
medicine, pharmacodiagnostics and Dx/Rx partnering. This emerging field is generating
strong interest from the healthcare industry and regulatory bodies, with the associated
market expanding as the importance of theranostics is recognised, especially in cancer.
Our new In Vitro Diagnostics Market Report & Analysis 2008-2023 report examines the
market for in vitro diagnostic solutions critically, through comprehensive primary and
secondary research. Importantly, visiongain discusses IVD in the context of the wider
healthcare market, with a strong emphasis on theranostics and related molecular
diagnostics/medicine. In addition to consultation with experts in industry - including full
interview transcripts - this research involved a detailed study of relevant documents,
industrial reports and current developments. Vitally, visiongain applied unique in-house
forecasting techniques and analysis of drivers and restraints. The result is a totally
independent in-depth market-based report with detailed analyses and informed opinion.
In particular, this report concentrates on the following essential aspects of the in vitro
diagnostics sector:
• Technologies that drive the IVD sector, including those related to theranostics
• Key industrial players in IVD - both established and emerging – including partnerships
• Forecasts of the global IVD market from 2008-2023 - including those of principal market
segments, both by disease area and technology
• Forecasts for IVD sales in leading national markets, including China and India
• Forecasts for theranostic applications - including therapeutic areas - from 2008-2023
• Drivers and opportunities in the IVD sector
• Restraints and threats in the IVD sector
• Assessments of relevant business models, technological solutions and associated issues
• Coverage of future trends in IVD and theranostics
• Insight from a comprehensive survey with relevant experts

• To receive a comprehensive analysis of the prospects for IVD from 2008-2023, including
sales by disease area, technology and country
• To discover predicted revenues, growth rates and other key metrics for theranostic
solutions from 2008-2023
• To receive the views of experts in the IVD sector regarding current and future trends
• To determine the forces that influence the market for IVD:
• Competition
• Drivers
• Restraints
• Strengths, weaknesses, opportunities and threats
• To find out where the IVD market is heading - both technologically and commercially
Visiongain predicts that the markets for IVD and theranostics will exhibit strong growth in
revenues from 2008-2023, with significant investments being made by far-sighted
companies and healthcare providers. Although still in its early stages of commercial
development, molecular diagnostics will increasingly gain acceptance from stakeholders in
healthcare. You should be benefiting from this opportunity. You and your company can
benefit as a result, gaining early market prominence from high-value products. You cannot
afford to ignore current developments in diagnostics, especially as personalised medicine
becomes an inevitable reality.
...more details
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023

In 2007, Amgen Inc - the world's largest biotechnology company - achieved total sales of
$14.7bn, despite a turbulent year marked by regulatory, pricing and reimbursement issues.
Amgen has now firmly established itself as a Top-20 international pharmaceutical
company. According to sales data for 2007, Amgen is also ranked as the 11th largest
pharmaceutical company worldwide based on total sales value. This is a remarkable
achievment for a biotechnology company founded in 1980.
Report Details
In 2007, Amgen Inc - the world’s largest biotechnology company - achieved total sales of
$14.7bn, despite a turbulent year marked by regulatory, pricing and reimbursement issues.
Amgen has now firmly established itself as a Top-20 international pharmaceutical
company. According to sales data for 2007, Amgen is also ranked as the 11th largest
pharmaceutical company worldwide based on total sales value. This is a remarkable
achievment for a biotechnology company founded in 1980.
This independent and unique report will help you to understand why Amgen is so
competitive and what roles it and similar companies will play in the global pharmaceutical
market from the present onwards. Amgen is a vital company for competitive analysis and
as an indicator of success factors required in the new competitive environment in
healthcare. Our new report Amgen - The Biotech Leader - Market Analyses and Outlook,
2008-2023 will help you to understand those developments and their significance for the
biotechnology and pharmaceutical industries, as well as related sectors.
Amgen’s proprietary products comprise human therapeutic drugs:
• Epogen (epoetin alfa)

• Aranesp (darbepoetin alfa)
• Neupogen (filgrastim)
• Neulasta (pegfilgrastim)
• Kineret (anakinra)
• Enbrel (etanercept).
Visiongain believes that the combined revenues for Amgen's key drugs will reach $20bn by
2012. Amgen’s leadership in the biotech sector over the years has been driven largely by
well-thought out strategic activities. Those corporate developments comprise key mergers
and acquisitions (M&As) and strategic alliances. Amgen, although presently going through
restructuring in some of its departments, clearly has a robust corporate strategy that should
serve it well for years to come, driving strong growth and further innovation. Moreover,
Amgen has a noteworthy commercial R&D pipeline that should generate significant
dividends in the long-term, visiongain believes.
Our new Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023 report
examines that company critically, with in-depth analysis. Importantly, visiongain discusses
Amgen in the context of the wider pharmaceutical market. This totally independent
market-based research involved a detailed study of commercial documents, databases,
company reports and relevant news. Importantly, visiongain applied techniques such as
financial forecasting, study of market shares, SWOT analysis and qualitative projections.
The result is a comprehensive market-based report with detailed analyses and informed
opinion.
In particular, Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
concentrates on the following essential aspects of Amgen and the market in which it
The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023
Visiongain have the pleasure of announcing the latest edition of their industry leading
report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the
world OTC market at present and predicts its sales revenues and trends from 2008-2023,
including drivers and restraints on the market.
Report Details
Visiongain have the pleasure of announcing the latest edition of their industry leading
report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the
world OTC market at present and predicts its sales revenues and trends from 2008-2023,
including drivers and restraints on the market. Sources used include industrial databases,
commercial and financial news, published reports and policy documents, interviews and
questionnaires. Visiongain applied financial forecasting, qualitative analyses and the
assessment of unmet needs to provide a comprehensive market-based report with detailed
analysis and informed opinion. The report examines the worldwide OTC market, breaking
down present and forecasted sales revenues into leading therapeutic categories and national
markets. Visiongain also provides forecasts for leading OTC brands.
In particular, this report concentrates on the following essential aspects of the global
OTC industry:
• Major therapeutic areas treated by OTC products
• Key industrial players in the OTC market
• Financial forecasts covering the period 2008-2023, including leading brands, countries
and therapeutic areas
• Geographical breakdown of the market
• Sales of the highest-selling OTC brands and other relevant information
• Coverage of prescription-only to OTC switching in the pharma industry

• To receive a comprehensive analysis of the prospects for the OTC industry from 2008-
2023, including sales by therapeutic area and country
• To discover predicted revenues, growth rates and other key metrics for OTC
pharmaceuticals from 2008-2023, including those of leading brands
• To discover possible future OTC switching candidates
• To determine the forces that influence the OTC market:
• Competition
Visiongain forecasts that OTC pharmaceutical sales will almost double from 2007 levels
by 2023. In the period 2008-2023, the worldwide OTC market will undergo a period of
dynamic change. Increasingly aging populations and rising incidence of lifestyle diseases,
as well as the need to reduce healthcare costs, will open up new therapeutic areas for OTC
switching. Likewise, sales of existing OTC products will rise. At the same time, changes in
retail patterns and new ways of advertising will open up access to OTC drugs to a public
better educated and more interested in self-medication than at any previous time. Taking
advantage of such opportunities will take considerable skill in a crowded and competitive
marketplace. Consequently, the commercial prospects are very good for companies well
placed to serve those growing needs. In these difficult times for the global pharmaceutical
industry, OTC sales will become increasingly important, visiongain concludes.
...more details
The Pharmaceutical Wholesale and Distribution Industry Outlook &

Analysis 2008
The major problem facing the Wholesale & Distribution industry is its low profit margin
which is in the region of only 1-2%. However, this market is entering into a crucial period
with many key products losing patent protection, facing heavy generic
competition.
Report Details
The major problem facing the Wholesale & Distribution industry is its low profit margin
which is in the region of only 1-2%. However, this market is entering into a crucial period
with many key products losing patent protection, facing heavy generic competition. As
generics are priced lower than their branded counterparts, the actual dollar profit on them
taken by W&D companies, for their movement, is reduced. In the light of this, other key
factors such as new pricing and distribution models are also discussed in more detail. Other
important issues that are affecting the industry and discussed in detail include:
1. Drug Counterfeiting
2. Direct-to-Pharmacy Distribution
3. Parallel Trade
4. Canada and US Drug Reimportation
5. Internet drugs: Mail Order and On-line Pharmacies.
The objectives of this report are to understand the W&D industry, why it occurs, who it
affects, different natures of wholesale-distribution and what kinds of strategies are
involved. Wholesale-Distribution has both pros and cons for different healthcare
stakeholders. Wholesale-Distribution is a complex area, where there are many “grey”
areas.
In particular, The Pharmaceutical Wholesale and Distribution Sector concentrates on the

following essential aspects of the industry:
• Discussion of the current W&D market

• Forecast of the big three US wholesalers from 2008-2013
• Drivers and restraints facing the W&D market
• Opportunities and threats facing the W&D market
• Commercial prospects for the W&D market
• Discussion of unmet needs
This report examines the industry critically through a comprehensive review of available
information, including that from commercial databases and other highly relevant sources,
including SWOT analysis. Visiongain applies financial forecasting, qualitative analyses
and the assessment of unmet needs to provide a comprehensive market report with detailed
analysis and informed opinion.

• To receive a comprehensive analysis of the prospects for the W&D market
• To discover predicted revenues, growth rates and other key metrics for the big three US
wholesalers from 2008-2013
• To determine key activities of leading pharmaceutical manufacturers
• To determine the forces that influence the W&D market
• Drivers
• Restraints
• Strengths, weaknesses, opportunities and threats (SWOT analysis)
• To find out where the W&D industry is heading - both technologically and commercially
...more details
The Indian Pharmaceutical Market

The pharmaceutical industry is one of the fastest growing sectors in Indian economy.
Visiongain predicts that market for pharmaceuticals in India has strong potential for
increased growth from 2008 right through to 2023. The industry's leading Indian Pharma
report contains unique market-based research, including detailed interviews with key
opinion leaders based in India and abroad.
Report Details
The pharmaceutical industry is one of the fastest growing sectors in Indian economy.
Visiongain predicts that market for pharmaceuticals in India has strong potential for
increased growth from 2008 right through to 2023. The industry’s leading Indian Pharma
report contains unique market-based research, including detailed interviews with key
opinion leaders based in India and abroad. Importantly, the report forecasts the overall
Indian pharmaceutical market from 2008 to 2023, as well as that of many important market
segments. Other key metrics are also included throughout the report. This is your
opportunity to gain critical insight into the potential and inner workings of one of the
world’s most important healthcare markets from the present onwards.
This new visiongain report describes India’s domestic as well as export market for
pharmaceuticals. India has had a strong domestic pharmaceutical industry and a rapidly
expanding market with a population of over a billion and a rapidly expanding economy.
Prevalence values of many diseases are likely to increase with expansion of population,
urbanisation and with higher identification rates in the coming decade. India's
pharmaceutical market is increasingly important in global pharma, with both domestic and
foreign companies benefiting. Healthcare provision – both public and private – is
improving, leading to fast-expanding markets for healthcare products, especially modern
pharmaceuticals, visiongain concludes.
Outsourcing for Contract Research and Manufacturing Services from India
The report also analyses India’s role in pharma outsourcing services. India is emerging as a
competitive outsourcing hub and is playing a major role in the global pharmaceutical
industry in manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates for
drug makers. Global pharmaceutical companies are establishing long-term relationships
with Indian manufacturing companies and contract research providers in India.
Generic drugs produced in India are increasingly being accepted worldwide, with leading
companies such as Ranbaxy, Cipla and Dr. Reddy’s paving the way for others. Indian
companies have increasingly taken on outsourced manufacturing for foreign clients, in
addition to marketing pharmaceuticals themselves. There are also new drug development
programmes by Indian companies, with eventual international market launches.
Outsourcing to India has proven to be effective in saving costs and valuable developmental
time. The Indian pharmaceutical industry has taken an important role in global pharma, not
only as a manufacturer of generic drugs and APIs but also of new formulations.
Increasing costs for research and development and low productivity have compelled major
pharmaceutical companies worldwide to outsource part of their research and
manufacturing activities to lower-cost, developing nations such as India and China. India's
emphasis on research and development and new drug discovery is growing. Furthermore,
India is emerging as the preferred destination for outsourcing clinical trials, with both high
quality and lower costs achieved there.
• With the introduction of ‘product patent regime’ in 2005, India is expected to receive
further investment from international pharmaceutical companies in the years ahead
• Global pharmaceutical companies are establishing long-term relationships with Indian
pharmaceutical companies and the contract manufacturing affiliates in India, in addition to
establishing manufacturing, R&D and marketing bases there
In this report you will receive the following essential information for understanding the
Indian pharma market and industry:
• The value of the Indian pharmaceutical market and its principal market segments from
2008 to 2023
• Exports values of the Indian pharmaceutical sector present and future
• Which current or future therapies that will drive the market for India’s pharmaceutical
industry from 2008 to 2023
• Market drivers and restraints, including a comprehensive SWOT analysis
• Comprehensive views of key opinion leaders on Indian pharma
• The companies involved in the market and their business strategy
• What are the forecasts for sales for each of the therapeutic areas
• What is the present state of disease prevalence and future trends there
• What contract research and manufacturing opportunities exist for ‘new comers’
This Report is essential reading for the Following Professionals, Amongst Others:
• Investors in the India’s pharmaceutical industry

• Business managers of multinational companies
• Business managers of India’s domestic companies
• Business managers of pharmaceutical industry related to outsourcing
• Researchers, analysts and academics interested in India’s pharmaceutical industry
• Senior staff in healthcare authorities relevant to India
Currently, India's largest selling medicines are anti-infective agents, but the fast growing
areas are the lifestyle-related diseases, the foreign multinational companies will benefit
from selling innovative treatments for these conditions.
With increasing prevalence of diseases of aging and lifestyle-related diseases associated

with greater affluence, India's pharmaceutical market will continue to increase steadily in
sales value from 2008 onwards. Furthermore, with rapid increase in drug resistance for
anti-infective agents like anti-TB, anti-malarial and other antibiotics, visiongain further
emphasises that there will be a particularly strong market for most types of pharmaceutical
agents – both new and established - from 2008 to 2023.
...more details
Lipitor Market analysis and forecasts Report

In 2006, Pfizer's Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the
best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly
driven the overall revenue margins of the cardiovascular segment, as this area continues to
dominate the pharmaceutical market.
Report Details
In 2006, Pfizer’s Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the
best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly
driven the overall revenue margins of the cardiovascular segment, as this area continues to
dominate the pharmaceutical market. Despite the maturing status of Lipitor, the drug has
repeatedly maintained steady growth over the past 5 years, crowding out the yearly
revenues of other lipid-regulating blockbuster drugs: Merck& Co’s Zocor and Zetia,
Astrazeneca’s Crestor, Abbott’s Tricor and Bristol Myers Squibb’s Pravacol.
However, as Lipitor’s blockbuster revenue is seriously threatened by imminent patent

expiration in some of the drug’s largest markets such as the US, Japan and the UK, there is
significant unrest between Pfizer’s key stakeholders about the future of the drug.
Principally, amongst the heightened Lipitor topics are the imminent exposure of the $1
billion annual drug sales or more, as well as the fast expanding generic market in which
India’s Ranbaxy is a dominant force.
What questions does the report answer?
• Has the success of Pfizer’s Lipitor been overstated?

• Did Pfizer create a monster in Lipitor?
• Have Lipitor sales redefined the bounds that pharmaceutical margins can now reach?
• How imminent is Lipitor patent expiration?
• Which key markets will suffer the consequence of Lipitor expiry?
• Is Ranbaxy ready for generic Lipitor?
• Do the fast developing markets, CEE and the Latin America segment hold the key to
future sales after Lipitor’s patent expiration?
• Is Lipitor a victim of the struggling Blockbuster Model?
• What is next for Lipitor?
As Pfizer’s Lipitor struggles to fend off the immediate entry of Ranbaxy’s generic Lipitor,
in key markets, the legal challenges surrounding the number one drug have set a new
benchmark for pharmaceutical companies protecting branded products. Industry observers
including Visiongain predicts that Pfizer’s crises are far from over, as the high revenue
streams of Lipitor will experience significant challenges before the commencement of the
next decade.
Moreover, Pfizer’s lack of success to replace Lipitor with Torcetrapib has escalated the
company’s near-term battles besides the ever-tighter regulatory hurdles, reduced R&D
efficiency and increased competition, creating formidable therapeutic challenges as
healthcare payers influence pricing. Nevertheless, there are strong drivers of growth
including unmet therapeutic needs, the rising incidence of multiple diseases, ageing
populations, the rising living standards and fast-developing geographical markets. The
future of Lipitor is therefore vitally important to Pfizer, especially in this uncertain period
of economic changes and pressures.
This report includes detailed five-year forecasts over the period 2008-2013, and NOW
features 10 and 15-year forecasts to help you understand the medium-term prospects for
these markets.
Why You Must Buy This Report:
This unique in-depth management report examines the future prospects for Lipitor from
2008-2023. It delivers direct to you future sales forecasts for leading Lipitor in all seven
major markets (7MM). This detailed report highlights the most compelling must know
issues- Lipitor’s patent contention by Pfizer in both 7MM and other markets in order to
block Ranbaxy’s immediate penetration of generic Lipitor. In light of healthcare drug bills
increasing exponentially, generic Lipitor will be welcomed by managed care organisations
(MCO) and further widen the generic revenue margins, visiongain concludes. This report
also tackles Lipitor’s significant developments, potential opportunities on the market and
important contemporary matters, especially commercial drivers and restraints.
...more details
Chinese Pharmaceutical Outlook 2008-2023

This brand new report examines the prospects for the growth of pharmaceutical revenues
in China. Visiongain predicts that total pharmaceutical revenues in China will increase
from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase,
one that will represent a near tripling of total sales over six years. Strong growth will
continue well beyond that period, as this report shows and explains.
Report Details
This brand new report examines the prospects for the growth of pharmaceutical revenues
in China. Visiongain predicts that total pharmaceutical revenues in China will increase
from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase,
one that will represent a near tripling of total sales over six years. Strong growth will
continue well beyond that period, as this report shows and explains.
Over 220 pages full of analysis, graphs, tables and charts – available to you today.
If you are interested in pharmaceutical business in China, you cannot afford to be without
this report by visiongain’s leading authority on developing pharmaceutical markets.
• The growth of pharmaceutical markets in the developing nations has the potential to
offset the slowdown of sales growth in developed markets of North America, Europe and
Japan.
• Visiongain predicts that China will exhibit very strong pharma sales growth from 2008-
2023. Rapid economic growth and a vast, currently under-served population, will drive that
expansion. There will be significant growth in sales of both branded and generic drugs
through increasing demand from both public and private healthcare sectors.
Visiongain’s Chinese Pharmaceutical Outlook 2008-2023 examines the exciting Chinese

pharmaceutical market and industrial sector critically through comprehensive research and
analysis. Visiongain applied techniques such as financial forecasting, surveying of key
opinion leaders, SWOT analyses and discussion of qualitative factors. Societal, political,
economic and commercial issues are covered. The result is a comprehensive market-based
report with detailed analysis and informed opinion. This original 220+ page study contains
57 tables and 47 figures. We invite you to examine the table of contents included here.
In particular, visiongain’s Chinese Pharmaceutical Outlook 2008-2023 concentrates on the

following themes:
• A forecast of the global pharmaceutical market from 2007-2023, with key issues
discussed
• Forecasts of sales revenues and growth rates for Chinese pharmaceutical sales from 2007-
2023, including key market segments such as Rx, OTC, domestic and foreign sales – all
with comprehensive discussion
• Forecasts of sales for leading therapeutic areas and pharma products
• Revenue forecasts for clinical outsourcing in China and relevant discussion
• Revenue forecasts for contract manufacturing in China and relevant discussion
• Drivers and opportunities in the Chinese pharmaceutical sector
• Restraints and threats in that market and industry
• Discussion of key domestic players and important therapeutic areas, including
biotechnology, drug development and joint ventures
• Discussion of regulatory, societal and economic issues

• To receive a comprehensive analysis of the Chinese pharma market and industry from
2007-2023, with both quantitative and qualitative aspects covered
• To discover predicted revenues, sales growth rates and other key metrics for the Chinese
pharma sector from 2006-2023
• To determine the forces that influence pharmaceutical sales and related developments in
China:
• Competitive characteristics of the market and industry
• Regulatory, technological, societal and political issues
• Drivers and restraints
• Expert opinion from China, as obtained by visiongain
• To find out where the Chinese market is heading - both commercially and technologically
- including regulatory issues
• To determine key activities of leading companies
• To receive a comprehensive discussion of healthcare provision in China, both public and
private.
The dominant pharmaceutical markets of North America, Western Europe and Japan
currently account for over 80% of revenues for prescription drugs worldwide. However,
there is great concern about the relatively low growth of those established markets in
recent years. Consequently, international pharmaceutical companies are striving to raise
their profiles in the developing markets of Asia, Latin America and Eastern/Central
Europe. Principal amongst those developing markets is the emergent demographic and
economic colossus of China.
Growth of the pharmaceutical markets in developing nations will clearly surpass that of the
established markets throughout the foreseeable future. That situation will provide one of
the greatest opportunities ever available to the international pharmaceutical industry. Those
strongly growing national economies drive the reform and broadening of healthcare
systems, with increasing sales in all healthcare sectors. Improvements in both the quality
and reach of these healthcare provisions will drive the sales of branded and generic drugs
in particular. This report will help you to understand those developments and opportunities.
...more details
Pharmaceutical Control of Blood Diseases Market Analysis & Forecasts

Report 2008
In 2007, blood diseases cost the US's economy $114bn. In 2004, a reported 232,000 deaths
in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding
disorders, white blood cell disorders and thrombosis collectively.
Report Details
In 2007, blood diseases cost the US's economy $114bn. In 2004, a reported 232,000 deaths
in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding
disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to
immunological defence to clotting, blood has vital physiological functions, and clear,
expensive treatments. This brand new blood diseases treatments report breaks down
therapies into four main groups:
• Antithrombotics
• Anti-anaemics
• Clotting Factors
• Others
In 2006 visiongain valued this market at $37406m, But do you know how the blood
diseases treatments market will fare 5, 10 and 15 years from now? Will it increase in sales
and bring in significant profits or will it be rocked by widespread patent expiration and
ensuing generic competition? This report provides these answers, with detailed quantitative
and qualitative analysis. This is information every player in the blood diseases treatments
market should not be without.
Visiongain's new Pharmaceutical Control of Blood Diseases Market Analysis & Forecasts
Report 2008 covers:
• An in-depth analysis of the major blood diseases and treatments
• Discussion of most effective innovative treatments for blood diseases
• Trends in the overall world blood diseases treatments market, with detailed market
forecasts from 2008 to 2023
• Reasons behind the trends
• A breakdown of the world market into the principal market segments, with forecasts and
predictions of future market share values
• Sales forecasts of the leading drugs in each sub-market
• A SWOT analysis of the blood disorders market
• Discussion of relevant market drivers and restraints
• A geographical breakdown of relevant global sales trends into the leading national
markets
• Pipeline developments in blood disorders
This study was achieved through research of relevant news, company reports, expert
opinion, academic literature and gold-standard IMS databases. Financial forecasting based
upon in-depth research was performed, with accompanying SWOT analyses. The result is a
comprehensive market-based study with extensive analysis and informed opinion.

This 115+ page report features over 25 tables, 50 graphs, market forecasts, current news,
detailed insight, the latest developments, all with up-to-date analysis and informed opinion.
This visiongain report is a vital aid to your gaining an understanding of this important
market sector, giving your company 'the edge' on its competitors.
Importantly this report gives answers to relevant questions such as:

• How will sales for blood disorder treatments change from 2006-2013 and beyond?
• What is the market share of the four classes of treatments and how will they change in the
years ahead?
• What are the top ten drugs in the blood diseases treatments market currently – how will
they fare from now until 2013?
• Which group of treatments will contract the most over the next five years?
• Which drugs dominate each treatment group, present and future?
• What are the main issues facing the market worldwide, both present and up to 2023?
• Where will the main opportunities lie from now onwards?
• Will the US continue to dominate the blood diseases treatments market? Where do the
other leading pharmaceutical nations stand?
• In which stages of development are relevant pipeline products and what are their
prospects?
...more details
Sleep Disorders: Market Analysis 2008-2018

The market penetration for insomnia drugs has not reached saturation point. Opportunities
remain. But with the introduction of several new products the market is set to see changes,
but expansion. This expansion is based on increased general awareness physicians better
comprehension of the significance of this disease and the positive role that a sleep
medication prescription plays.
Report Details
More than 80 sleep disorders have been identified. They affect over 200 million people
worldwide. The report focuses on the market for following sleep disorders:
• Insomnia
• Restless legs syndrome (RLS)
• Narcolepsy and
• Obstructive Sleep Apnoea / Hypopnea Syndrome (OSAHS)
The market penetration for insomnia drugs has not reached saturation point. Opportunities
remain. But with the introduction of several new products the market is set to see changes,
but expansion. This expansion is based on increased general awareness physicians better
comprehension of the significance of this disease and the positive role that a sleep
medication prescription plays.
At present time there are several prescription sleeping medications available to treat
insomnia. The market-focus has been driven by the production of sleep medications with
less side-effects and danger of overdose. Prescription benzodiazepines and newer non-
benzodiazepine hypnotics developed in the 1990s, such as Imovane, Ambien and Sonata
will continue to be the most prescribed. Benzodiazepines are widely used to treat an
underlying neurological disorder which is often the underlying cause of insomnia, e.g.
anxiety and depression.
Visiongain predicts that market share by volume for insomnia in the US will change
significantly from 2008 to 2018. Ambien IR lost its patent protection in April 2007, which
opened to generic competition for Zolpidem. Ambien will remain the market leader for the
short term, but what will over take it? A generic version of Ambien is expected to achieve
strong market share by volume as there is a great demand for zolpidem tartrate for
insomnia.
The market share for insomnia treatment will gradually rise after 2012, which will be due
to:
• Market expansion of existing expensive medications into Europe and Japan in particular
• Market penetration of new medications currently in pipeline.
Other drugs dealt with in this report include:
• Modafinil (Provigil) is the first in a new class of wake-promoting drugs and is currently
approved in more than 20 countries for the treatment of excessive daytime sleepiness
associated with narcolepsy.
• Provigil is quickly replacing Ritalin, and other CNS stimulants, as the medication of
choice for treating daytime sleepiness in narcolepsy. The FDA granted modafinil (Provigil)
orphan drug status in 1993.
• Modafinil was initially launched in the US in 1999 for the treatment of narcolepsy. In
2004, modafinil became FDA-approved prescription medicine for the treatment of
excessive sleepiness associated with Obstructive Sleep Apnoea/Hypopnea Syndrome
(OSAHS) and Shift Workers Sleep Disorder (SWSD).
• Requip (ropinirole) became the first and only FDA-approved drug treatment for moderate
to severe primary Restless Legs Syndrome (RLS) in 2005.
Key findings that will broaden the scope of the sleep disorders market:
• Over the next decade, the development and improvement of sleep disorders therapies will
primarily depend on the success of burgeoning technology and innovative approaches.
• It is possible to purchase prescription medications online without producing a
prescription. Purchase of online sleep medications has increased and will continue to
evolve over the next years.
• The impact of DTC advertising has created an improved awareness of available insomnia
treatment.
• This is likely to increase as DTC advertising continues to prosper and the culture
becomes more accepting towards insomnia treatment. Visiongain expects the market for
sleep disorders to increase, driven by a growing awareness of sleep disorders and by
campaigns to promote sleep medications, both by DTC advertising and consumer
education. The relaxation of DTC marketing restrictions in the 1990s in the US set the
stage for a flow for both branded and unbranded advertising and promotional programmes.
Those regulations are prompting more responsible DTC advertising on the industry's part.
• The FDA has requested that all manufacturers of sedative-hypnotic drug products, a class
of drugs used to induce and/or maintain sleep, strengthen their product labelling to include
stronger warnings concerning potential risks.
• The Committee for Medicinal Products in Human Use (CHMP) of the European
Medicines Agency (EMEA) approved Neurim's Circadin a prolonged-release melatonin as
monotherapy for the short-term treatment of primary insomnia characterised by poor
quality of sleep in patients aged 55 or over. Neurim is actively seeking strategic alliances
for the major European markets.
• Which current or future therapies will drive the sleep disorders market from 2008 to
2018?
• The key companies involved in the market and their analysis?
• What is the patient identification rate for each of the therapeutic areas?
• What is the present state of the disease awareness?
• What R&D opportunities exist for ‘new comers’?
Why should you buy this report?
• This report focuses on the marketed medications and the pipeline development for sleep
disorders from 2008 to 2018. It also discusses the strength and weakness of products,
along with the opportunities and threats facing the market.
• The report describes world market situation for sleep disorders, namely insomnia,
narcolepsy, RLS and OSAHS, with forecasts made for all key products. It also describes
the insomnia market situation in the seven major world markets for sleep medications: the
US, Japan, France, Germany, Italy, Spain and the UK, with forecasts for key products.
• The report provides transcripts of visiongain’s interviews with experts in the field of sleep
disorders, which reviews the future direction of the sleep disorders treatment market.
...more details
The Antibacterial Drug Market: Analysis 2008-2013

This brand new market analysis by visiongain examines the prospects for antibacterial
drugs from 2008-2013, including sales forecasts for leading pharmaceutical products. The
antibacterial market is large in terms of disease area as well as the different drug classes
used to treat these infections. However, this market is entering into a crucial period with
many key products losing patent protection, facing heavy generic competition.
This brand new market analysis by visiongain examines the prospects for antibacterial
drugs from 2008-2013, including sales forecasts for leading pharmaceutical products. The
antibacterial market is large in terms of disease area as well as the different drug classes
used to treat these infections. However, this market is entering into a crucial period with
many key products losing patent protection, facing heavy generic competition. In the light
of this, including other factors, visiongain predicts this market to decline in revenues – but
which products will suffer most? How can you fight this generic competition? The
antibacterial drug market generated revenues of $30274m in 2006 – but what will it be in
2013? Only this brand new report will tell you.
The antibacterial market only contained one blockbuster drug in 2006, this being Johnson
& Johnson’s Levaquin. Visiongain predicts that there will be room for one more
blockbuster drug as Levaquin will lose patent protection. This detailed report also
This report will specifically analyse the world markets for the following classes of
antibacterials:
• Cephalosporins
• Macrolides
• Penicillins
• Fluoroquinolones
• Carbapenems
• Miscellaneous.
The group 'miscellaneous' is an assorted group of antibacterials which includes the minor
classes: the tetracyclines, aminoglycosides, glycopeptides and sulphonamides plus
individual antibacterials such as Zyvox and Vancocin.
The Antibacterial Drug Market Analysis 2008 examines the market critically through a
comprehensive review of available information. Sources include industrial databases,
commercial news, published reports, economic research and consultation with experts.
Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet
needs to provide a comprehensive market report with detailed analysis and informed
opinion.
In particular, The Antibacterial Drug Market concentrates on the following essential

aspects of the market:
• Discussion of the current pharmaceutical market

• Forecast of the worldwide pharmaceutical market from 2008-2013
• Drivers and restraints facing the antibacterial drug market
• Opportunities and threats facing the antibacterial drug market
• Growth of the antibacterial drugs market between 2008-2013
• Commercial prospects for the market-leading drugs, with sales forecasts from 2008-2013
• Individual forecasts of the leading drug classes from 2008-2013
• Pipeline developments with blockbuster potential
• Discussion of unmet therapeutic needs and relative advantages of products
• To receive a comprehensive analysis of the prospects for antibacterial drugs from 2008-
2013
pharmaceutical treatments from 2008-2013
• To determine the forces that influence the market for antibacterial drugs:
• Drivers
• Restraints
• To find out where the market is heading - both technologically and commercially
...more details
Generic League
The generic industry is a fast evolving market; with significant lucrative opportunities. The
generic market is structurally set to experience high growth potential. That wave is partly
driven by cost-containment in several national healthcare sectors and partly by the need for
governments to promote the use of generic products over high-priced originator products
without compromising quality.
Report Details
The generic industry is a fast evolving market; with significant lucrative opportunities. The
generic market is structurally set to experience high growth potential. That wave is partly
driven by cost-containment in several national healthcare sectors and partly by the need for
governments to promote the use of generic products over high-priced originator products
without compromising quality.
In 2006, the global generics market attained strong revenues of approximately $65bn, up
by 12% in comparison with $58bn in 2005. However, during the same period, the Top Ten
leading generic suppliers generated total revenues of $27.9bn, up by a growth rate of 34%.
The Top Five Companies within that sector experienced significant revenues, with market
growth largely driven by significant commercial activities, key Mergers and Acquisition
(M&A) and launch of new product in the leading markets.
In light, of the significant number of proprietary branded pharmaceuticals approaching

patent expiration in the near-term, visiongain predicts that the generic market is set to
experience further market expansion during the forecast period. Visiongain also predicts
that by 2023, the Top Ten leading generic suppliers will experience CAGR of 7%. That
significant CAGR, will be driven by generic versions of leading blockbuster drugs
presently estimated at $100bn, nearing patent expiration during 2008-2012.
Prominently, amongst the products with looming patent expirations are drugs such as:
• Pfizer's Lipitor
• AstraZeneca's Nexium
• Bristol Myers Squib's Plavix
• Pfizer's Norvasc
• Lilly's Zyprexa
• Janssen's Risperdal
• Wyeth's Effexor
In 2007, a total of 14 drugs came of patent in the US market. In 2008, a total of 14 drugs
are expected to lose patent protection in the US market. In 2009, five drugs are predicted to
becoming off-patent in the US market. On the 24 of March 2010, the world's highest
selling drug, Pfizer's Liptor will come off-patent in the US. In the EU market, UCB's
Keppra and four other medicines are expected to lose patent protection. In 2011, 10 major
drugs in the US market will also become exposed to generic competition. An estimated 11
drugs will experience generic competition in the EU market during the same year.
Significant among these drugs will be Lipitor and Zyprexa.
Moreover, the generic market is projected to further expand through the growing uptake of
biogeneric/ biosimilar products. In 2006, biological drugs, the products of biotechnology
generated total revenues of $40bn. The US market alone, accounted for a significant
proportion of total worldwide sales. Presently, in the EU, the growing popularity of these
products are gaining newer heights, with managed care organisations (MCOs), healthcare
providers and payers amongst others increasingly requesting these medicines as a
significant cost-saving strategy. However, by 2010, an estimated 24 biologic drugs will
near patent expiration opening up the market for generic possibilities.
Visiongain’s market analysis forecast a-to- be lucrative era during the mid-term of our
forecast where we believe, the Top Ten generic suppliers will see strong sales growth
leveraged through licensing of new products.
With Top Ten company-by-company forecast focus on regions:
Asia
• Teva (Asia/ Israel)
Europe
• Actavis (Finland)
• Merck KGaA (Germany)
• Ratiopharm (Germany)
• Sandoz (Switzerland)
• Stada (Germany)
North America
• Apotex (Canada)
• Barr (US)
• Mylan (US)
• Watson (US)
This report includes detailed five-year forecasts over the period 2007-2012, and NOW
features 10 and 15-year forecasts to help you understand the medium-term prospects for
these markets.
Why You Must Buy This Report:
This report features in-depth primary research, tables, graphs and charts, news, insights,
the past and present developments in Market. This report will provide you with the
complete understanding of operations of Top Ten companies that has driven their corporate
growth in recent times. In addition, the report sheds significant emphasis on key strategies
that will drive year-on-year sales growth of their leading products. Despite the lucrative
opportunities presented to the leading companies through patent expirations, the visiongain
reports analyses the key battles that the leading Top Ten generic companies will face
during the same period.
This visiongain report is the single tool to equip you with the latest trends in all regional
markets and why all (stakeholders) are opting for cheaper generic medicine, that are
equally potent as their originator versions. Visiongain recommends this astute report to the
major players in the field as it will arm you with the major legal challenges that leading
companies face to date. The report, will also inform you on how the Top Ten generic
companies are positioning themselves in facing the rising inherent cost of R&D
expenditure especially on difficult-to-manufacture biogeneric/ biosimilars. In addition, the
reports present a 360 degrees overview of requirements set by major regulatory authorities
for larger evidence of clinical data before any authorisation.
When you buy this report, you will also get an understanding, through our overview; of
how present changes in Governmental Pharmaceutical Policies with respect to cost-cutting
coupled with major hurdles by that the Top Ten generic suppliers will have to overcome in
the growing presence of price erosion /sensitivity in key and emerging markets. The Top
Ten Generic League Market Analysis & Forecasts 2007-2023 report is a must buy, because
it presents in-depth and unbiased financial analysis for the near-term, medium-term and the
long-term, market dynamics.
When you buy the Visiongain 2008 Top Ten Generic League report, you will be buying
current and vital information on the vast array of commercial opportunities marked for
potential success in the long-term treatment of the generic market.
• Who are the generic market leaders?

• Which regions dominate the generic market?
• Which of the Top Ten companies conducted key M&As to bolster product pipeline?
• Have the M&As been successful in expanding product range?
• Is the cost of branded medicines justifiable by Big Pharma?
• How will the Top Ten account for future revenues?
• Will the Top Ten continue to experience market share expansion?
• How will the Top Ten overcome the legal battles?
• Are the legal battles really worth the cost of the generic medicines?
• What direction is Biogenerics marketing taking?
• Will the EU regulatory bodies narrow the generic gap between the US?
• Will the Top Ten themselves be acquired under mounting pressure of strong market
competitions?
• Will the rising cost of R&D, deter the Top Ten from investing?
• Are the voices of managed care organisations (MCOs), healthcare providers and payers
driving down sales of Big Pharm’s blockbusters?
• Is the EU a “nice-to-operate-in” or a “must-operate-in” market for the Top Ten?
...more details
The Antipsychotics Market Insight & Analysis 2008

The total antipsychotics market revenue in 2006 was $18.1bn. Visiongain predicts that total
revenues in the antipsychotics market will peak to $18.6bn by 2007. But what will it be in
2012?
Report Details
The total antipsychotics market revenue in 2006 was $18.1bn. Visiongain predicts that total
revenues in the antipsychotics market will peak to $18.6bn by 2007. But what will it be in
2012? This report will tell you.
This in-depth market analysis examines prospects for antipsychotic drugs right through to
2012, including sales forecasts for leading products. The antipsychotics market will face
decreasing growth throughout the forecast period, due to the patent expiry of leading
blockbuster drugs. Safety concerns over the current antipsychotics along with high prices,
will also contribute to decreased growth in this market.
The antipsychotics market currently contains four blockbuster drugs; Zyprexa, Risperdal,
Seroquel and Abilify. Visiongain predicts that a fifth drug will also reach blockbuster status
by 2008. This detailed report also highlights pipeline developments and important
contemporary issues, especially commercial drivers and restraints.
According to the National Alliance for Research on Schizophrenia and Depression,
approximately 22.1 per cent of American adults (approximately 64 million people) suffer
from a diagnosable mental illness in any given year. Of these, it is estimated that over 2
million suffer from schizophrenia. Similarly, approximately 18.8 million people have a
depressive disorder, with approximately 2.3 to 3 million suffering from bipolar disorder.
The Antipsychotic Drugs Market Insight and Analysis 2008 examines the market critically
through a comprehensive review of available information. Sources include primary
research unavailable elsewhere, in-house and industrial databases, commercial news,
published reports, economic research and consultation with experts. Visiongain applies
financial forecasting, qualitative analyses and the assessment of unmet needs to provide a
comprehensive market report with detailed analysis and informed opinion.
In particular, The Antipsychotics Market concentrates on the following essential aspects of

the market:

• Drivers and restraints facing the antipsychotics market
• Opportunities and threats facing the antipsychotics market
• Growth of the antipsychotic drugs market between 2007-2012
• To receive a comprehensive analysis of the prospects for antipsychotic drugs from 2007-
2012
• To determine the forces that influence the market for antipsychotic products:
• Competitive characteristics of the market Drivers
• Restraints
• To find out where the antipsychotics market is heading - both technologically and
commercially
The future of current and potential anti-psychotic blockbusters is vitally important to each
company. Off label allocation has seen companies write off funds for possible legal
actions. Zyprexa-maker Lilly set aside $1.2 billion to settle 31,000 claims and still faces
1,200 cases and a federal probe. Bristol-Myers Squibb, maker of Abilify, agreed to pay
$515 million last year, in part to settle off-label marketing allegations; the firms also face
thousands of additional claims. AstraZeneca has 8,000 suits pending for Seroquel.
This report concentrates on arguably the most exciting challenge facing the anti-psychotic
industry and regulators: how to adapt medicine to patient sub-populations and emerging
regulatory demands, improving safety and efficacy markedly. No pharmaceutical company
can afford to ignore those issues.
...more details
Respiratory Market Insight 2008

This brand new report examines the forthcoming prospects for respiratory drugs over the
next 5 year. With in-depth sales forecasts for leading pharmaceutical products, the report
has been produced to inform you of future developments and strategies. The respiratory
market generated revenues of $30503m in 2006, but what will it be in 2013,? Which year
will see it reach its peak?
Report Details
This brand new report examines the forthcoming prospects for respiratory drugs over the
next 5 year. With in-depth sales forecasts for leading pharmaceutical products, the report
has been produced to inform you of future developments and strategies. The respiratory
market generated revenues of $30503m in 2006, but what will it be in 2013,? Which year
will see it reach its peak? This report tells you.
The respiratory market contained ten blockbuster drugs in 2006, with the top three being;
Advair/Seretide, Singulair and Zyrtec. Visiongain predicts that there will be room for more
blockbusters as the current products lose patent protection. This detailed report also
The prevalence of respiratory diseases such as asthma, in the leading pharmaceutical

markets, has increased significantly over the past few decades. Although there is some
evidence to suggest that the rate of increase is slowing, we believe that the prevalence will
continue to increase and be a key driver of this market throughout the forecast period of the
report.
Sources include primary interviews and analysis unavailable elsewhere, in-house industry
databases, commercial news, published reports, economic research and consultation with
experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of
unmet needs to provide a comprehensive market report with detailed analysis and informed
opinion.
In particular, The Respiratory Market concentrates on the following essential aspects of the
market:

• Drivers and restraints facing the respiratory market
• Opportunities and threats facing the respiratory market
• Growth of the respiratory drugs market between 2008-2013
• Individual forecasts of the leading drug classes from 2008-2013
• To receive a comprehensive analysis of the prospects for respiratory drugs from 2008-
2013
• To determine the forces that influence the market for respiratory products:
• Drivers
• Restraints
• To find out where the market is heading - both technologically and commercially
Do you know what the market values of these major therapeutic areas of the respiratory
market are?
The report provides in-depth market analysis upon these areas, and extensively identifies
both prescription and OTC respiratory drugs by product type. The study also assess' the
challenges faced by respiratory companies, and what exciting market opportunities exist in
this up- and-coming therapeutic area.
This report features over 40 figures & graphs, 15 tables and charts, news, insights, the
latest developments and an in depth survey of the respiratory market with up-to-date
analysis. This report is a vital addition to gaining an understanding of this highly profitable
market sector and will give your company 'the edge' on your competitors. You can not
afford to be without this latest report from visiongain.
...more details
Live-Licensing & In-life testing: R&D Processes and Regulation for New Drugs,
2008-2020
Visiongain predict that the current phase I to IV clinical testing process will eventually be
selectively or wholly replaced by a system known as "in-life testing" or "live-licensing".
Those proposals involve cumulative testing of the drug throughout its lifecycle. The
industry would continually test drugs with smaller, more focused clinical trials. If a trial
shows efficacy and safety, a live license would be given, allowing the company to market
the drug in a limited manner.
Report Details
Visiongain predict that the current phase I to IV clinical testing process will eventually be
selectively or wholly replaced by a system known as “in-life” testing or “live” licensing.
Those proposals involve cumulative testing of the drug throughout its lifecycle. The
industry would continually test drugs with smaller, more focused clinical trials. If a trial
shows efficacy and safety, a live license would be given, allowing the company to market
the drug in a limited manner. Already, the FDA and the EMEA have shown favourable
interest in such developments - amongst other amendments to current practice.
In particular, R&D Processes and Regulation for New Drugs, 2008-2020, concentrates on
the following essential aspects of the market:
• Forward-looking development of R&D methods and regulatory policies in theory and

practice
• Discussion of the relevant technology and methods, including accompanying diagnostic
tests (theranostics/companion diagnostics)
• Discussion of un-met/under-met therapeutic needs and relative advantages of emerging
developmental methods and regulatory policy
• Discussion of the current global pharmaceutical market and where it is heading
• Drivers and restraints facing new drug development from 2008-2020
• Opportunities and threats facing drug development from 2008-2020, with SWOT analysis
• Detailed interviews with leading experts in regulatory affairs in academia and industry
• To receive a comprehensive analysis of the prospects for new drug development from
2008-2020
• The views of leading experts in regulatory affairs concerning present and future issues in
new drug development and regulatory trends
• To discover the most important existing and potential future regulatory developments
• Predictions for key developmental metrics that can be improved via the new methods and
regulatory initiatives
• To determine the forces that influence new drug development:
• Competitive characteristics
• Drivers
• Restraints
• To find out where pharmaceutical R&D is heading - both technologically and
commercially, with emphasis on all healthcare stakeholders.
Further clinical testing during the marketing of the drug could allow the marketing
restrictions to be gradually lifted, providing access to greater numbers of patients,
including an expansion of indications. This proposed testing system has the advantage of
allowing companies to gain revenues from the drug candidate earlier, while benefiting
patients earlier as well. The tests combined with treatment could also cut developmental
costs significantly, since large-scale clinical testing is very costly and time consuming. This
is a win-win situation for you and your company – you must be fully informed of it now.
Visiongain believes that in life testing/live licensing will be fully operative next decade.
The future of current and potential blockbusters is therefore vitally important to all
companies in the pharmaceutical sector, especially in this period of economic pressures
and regulatory uncertainty. This report concentrates on arguably the most exciting
challenge facing the industry and regulators: how to adapt medicine to patient sub-
populations and emerging regulatory demands, improving safety and efficacy markedly.
No pharmaceutical company can afford to ignore those issues.
...more details

Vision Gain Pharma Reports

Hochgeladen von

Dokumentinformationen

Originalbeschreibung:

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

Vision Gain Pharma Reports

Hochgeladen von

Copyright:

Verfügbare Formate

Visiongain ltd.

Telephone: +44 (0) 20 7336 6100

Stem Cells – The Hype & Hope – World Analysis 2009-2024

Comprehensive analysis of the global stem cells sector and market

Why you should buy this report:

You can order this report today

Contemporary disease-modifying drugs for MS are administered intravenously,

Comprehensive Market Analysis

Highlights of Statins: The World Market, 2009-2024 include:

Why you should buy this report:

Inflammatory Bowel Diseases: World Market Report 2009-2024

Why you should buy this report:

Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024

Why you should buy this report:

Smoking Cessation, 2009-2024 is a comprehensive analysis of the world smoking cessation

Why you should buy this report:

Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics - 2009-2023

Ophthalmic Pharmaceuticals, 2009-2023 - provides an in-depth analysis of the ophthalmic

Highlights of Ophthalmic Pharmaceuticals, 2009-2023 include:

Why you should buy this report:

The World Dermatological Market Outlook, 2009-2023

In particular, The World Dermatological Market Outlook, 2009-2023 concentrates on the

Why you should buy this report:

Top-10 Biotech Companies - Market Outlook, 2008-2023

Why you should buy this report:

Why you should buy this report

Despite the potentially great opportunities to be harnessed by generics companies in both

The Global Pain Market, 2008-2023

This report delivers:

Why you should buy this report:

The Global Anti-Addiction Market, 2008-2023

Visiongain has applied detailed financial forecasting and analysis of market/industry

Other highlights of The Global Anti-Addiction Market, 2008-2023 report include:

Why you should buy this report:

World Gastrointestinal Disorders Market 2008-2023

World Gastrointestinal Disorders Market 2008-2023 examines the GI market critically

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for the world gastrointestinal

The Japanese Pharmaceutical Market 2008-2023

In particular, this Japanese pharmaceutical market report from visiongain

Why you should buy this report:

Women's Reproductive Disorders Therapeutics 2008-2018

Oral Contraceptive Market

Lifecycle Management and Product Line Extension

Menopause and Hormone Replacement Therapy

Women’s Reproductive Disorders Therapeutics, 2008-2018 examines that market critically,

In particular, our new Women’s Reproductive Disorders Therapeutics, 2008-2018

Why You Should Buy This Report

This Report would be Useful to the Following Professionals, Amongst Others:

Global Antivirals Market Analysis & Forecasts 2008-2023

Why you should buy this report:

In particular, The Global Vaccines Market, 2008-2023 concentrates on the following

Therapeutic vaccines differ from currently-marketed vaccines. Instead of simply

Why you should buy this report:

Global Biotech Market Analysis and Forecasts, 2008-2023

- Includes Top 10 Therapy classes for biotech

You will not find this information available anywhere else.

Why you should buy this report:

Contract Pharma 2008-2023

In particular, the following factors have been highlighted in this report:

Why you should buy this report:

The report is intended for the following professionals, amongst others:

Osteoporosis & Bone Metabolism Disorders Market 2008-2023 Management Report